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ABSTRACT 
MODIFICATION AND IMPLEMENTATION OF THE RPC HETEROGENEOUS 
THORAX PHANTOM FOR VERIFICATION OF PROTON THERAPY TREATMENT 
PROCEDURES 
 
By: Anthony (Tony) Blatnica 
Chairperson of the Supervisory Committee: Geoffrey S. Ibbott, PhD. 
 
The Radiological Physics Center (RPC) provides heterogeneous phantoms that are used to 
evaluate radiation treatment procedures as part of a comprehensive quality assurance program for 
institutions participating in clinical trials. It was hypothesized that the existing RPC heterogeneous 
thorax phantom can be modified to assess lung tumor proton beam therapy procedures involving 
patient simulation, treatment planning, and treatment delivery, and could confirm agreement between 
the measured dose and calculated dose within 5%/3mm with a reproducibility of 5%. The Hounsfield 
Units (HU) for lung equivalent materials (balsa wood and cork) was measured using a CT scanner. 
The relative linear stopping power (RLSP) of these materials was measured. The linear energy 
transfer (LET) of Gafchromic EBT2 film was analyzed utilizing parallel and perpendicular 
orientations in a water tank and compared to ion chamber readings. Both parallel and perpendicular 
orientations displayed a quenching effect underperforming the ion chamber, with the parallel 
orientation showing an average 31 % difference and the perpendicular showing an average of 15% 
difference. Two treatment plans were created that delivered the prescribed dose to the target volume, 
while achieving low entrance doses. Both treatment plans were designed using smeared compensators 
and expanded apertures, as would be utilized for a patient in the clinic. Plan 1a contained two beams 
that were set to orthogonal angles and a zero degree couch kick. Plan 1b utilized two beams set to 10 
v 
 
and 80 degrees with a 15 degree couch kick. EBT2 film and TLD were inserted and the phantom was 
irradiated 3 times for each plan.  Both plans passed the criteria for the TLD measurements where the 
TLD values were within 7% of the dose calculated by Eclipse. Utilizing the 5%/3mm criteria, the 3 
trial average of overall pass rate was 71% for Plan 1a. The 3 trial average for the overall pass rate was 
76% for Plan 1b. The trials were then analyzed using RPC conventional lung treatment guidelines set 
forth by the RTOG: 5%/5mm, and an overall pass rate of 85%. Utilizing these criteria, only Plan 1b 
passed for all 3 trials, with an average overall pass rate of 89%.  
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
1.1 Introduction 
Lung cancer is a growing problem in the United States and the world in general. The 
American Cancer Society estimates that there will be 157,300 deaths (86,220 among men and 71,080 
among women) in the United States from lung cancer in 2010, accounting for about 28% of all 
cancer related deaths.  In addition, lung cancer occurs mainly in older people, with 2 out of 3 lung 
cancer diagnoses coming from people older than 65. (American Cancer Society 2010). Preservation 
of lung function is an important criterion in deciding treatment options for these patients.  Proton 
therapy allows for superior dose distributions to be delivered to the targets, and it has been suggested 
that this will allow for more conformal treatment without increasing the dose to the surrounding 
tissue, while escalating the dose to the tumor site (A. R. Smith 2006). Because of these reasons, 
proton therapy is beginning to be a treatment option that many with lung cancer are becoming 
interested in receiving. 
1.2 Statement of Problem 
As of March 15, 2010, the Advanced Technology Consortium has given guidelines for the 
use of proton therapy in National Cancer Institute (NCI) sponsored cooperative clinical trials.  
Before patient trials can begin, any participating institute must be appropriately credentialed to 
perform proton radiation therapy. This credentialing procedure also requires a successful site visit 
from the Radiological Physics Center (RPC) which will include the usage of an anthropomorphic 
phantom. The mission of the RPC is to assure the NCI and cooperative groups that the institutions 
participating in the trial are delivering consistent and comparable doses of radiation accurately (D. 
Followill 2010) . To enable this assurance, the RPC utilizes mail-able heterogeneous phantoms 
which contain both radiochromic film and thermoluminescent dosimeters (TLD). As of this writing, 
there are no heterogeneous phantoms that have been commissioned to evaluate proton lung therapy. 
There is an existing RPC thorax phantom that is used to evaluate standard photon radiation therapy 
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and intensity modulated radiation therapy (IMRT). The purpose of this study is to discover if there is 
a method to modify the existing phantom in such a way that the phantom can be utilized to evaluate 
proton lung treatment procedures. 
1.3 Proton Therapy 
1.3.1 HISTORY 
All atoms are composed of a nucleus surrounded by electrons. The particles that make up the 
nucleus are called nucleons, and can be either neutrons or protons. Proton particles were first 
proposed by Rutherford in 1919. Utilizing a natural radioactive source to provide energetic α 
particles, he bombarded nitrogen nuclei and showed that hydrogen nuclei were created, giving the 
name protons to these hydrogen nuclei. (Sundaresan 2001).   
In 1946, Robert R. Wilson discussed the possibilities of using “fast protons.” These protons 
could be accelerated to energies above 125MeV and perhaps as high as 400MeV to treat patients, 
and as such could penetrate deep enough into a patient to reach any part of the body.  A unique 
property of these protons is that as they pass though tissue, they follow a straight trajectory, allowing 
the proton beam to be used to treat a strictly localized region within the body. The total distance 
travelled by the protons along this trajectory is known as the range of the protons, and is determined 
by the amount of energy imparted to the protons by the accelerator. For protons accelerated to 
140MeV, the energy imparted over the last centimeter is almost six times that at the surface. (Wilson 
1946) This lower surface dose contributes to a tissue sparing effect on the entrance of the beam. The 
large deposit of energy at the the distal end of the proton’s range is known as the Bragg peak, and is 
immediately followed by a rapid decrease in dose, thus allowing a target to be treated with little to no 
exit dose. 
In 1990, Loma Linda University Medical Center (LLUMC) became the first hospital based 
proton facility in the United States. (Slater, et al. 1992) Until this point, patients were previously 
treated in the US using high energy protons only as part of research protocols at facilities where the 
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machines were primarily used for research.  The University of Texas M.D. Anderson Cancer Center 
(MDACC) Proton Therapy Center Houston (PTC-H) was commissioned in 2003 and opened for 
patient treatments in May 2006.  The PTC-H has four treatment rooms; three utilizing rotating 
gantries, and one with two horizontal beam lines with capabilities for both large- and small-field 
treatments. The rotating gantries utilize passive scattering in two rooms, and the third contains a 
scanning pencil beam, that can eventually be utilized for intensity modulated proton treatments. 
(Smith, et al. 2003) This study was performed at the M. D. Anderson facility. 
1.3.2 PROPERTIES OF PROTONS 
The proton is an elementary particle having a positive charge that is equal yet opposite to 
that of an electron. The mass of the proton is 1.6 x10-27 kg, which is approximately 1840 times larger 
than that of the mass of an electron. (Khan 2010)  
1.3.3 PROPERTIES OF THE PROTON BEAM 
Proton beams can be modified to manipulate the depth and shape of the beam. The energy 
loss properties of protons in matter can allow the range of the protons to be predicted based on the 
initial energy of the protons and the density of the materials through which they travel. As the 
protons pass through matter, they ionize the atoms that they encounter, gradually losing energy along 
the way predominately from inelastic collisions with electrons. The average rate of energy loss of a 
particle per unit path length in a specified medium is called the stopping power. The linear stopping 
power (−𝑑𝐸/𝑑𝑥) is the loss of energy (−𝑑𝐸) over some specified range (𝑑𝑥) and is measured in 
units of 𝑀𝑒𝑉/𝑐𝑚.  The linear energy transfer (LET) of the particle is determined by removing the 
dependence on the density of the medium from stopping power tables by calculating ranges in units 
of 𝑔/𝑐𝑚2. (Khan 2010) 
Stopping powers at higher energies, such as those used in proton therapy, are calculated 
according to Bethe’s formula (ICRU 1993), where the mass collision stopping power is shown 
below: 
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In the Bethe formula, 𝑟𝑒is the classical electron radius, 𝑚𝑐2 is the electron rest mass energy, 
𝜇 is the atomic mass unit, 𝛽 is the particle velocity in units of the velocity of light, 𝑍 is the atomic 
number, 𝐴 is the relative atomic mass of the target atom, and 𝑧 is the charge number of the projectile.  
𝐿(𝛽) is the stopping number and it depends upon 3 factors: 
1. The mean excitation energy of the medium, which quantifies the electron binding energy. 
The mean excitation potential is theoretically related to the orbital frequencies of electrons, 
and is usually determined from experimental data. 
2. The contribution to stopping power from protons interacting with K-shell electrons lessens 
as the velocity of the projectile decreases.  This is known as shell correction, and at low 
velocities, the assumption that electrons are stationary is not valid. 
3. The density-effect correction, which accounts for the reduction of the stopping power due to 
the incident particle polarizing the medium through which it travels. (ICRU 1993) 
The LET for charged particles, such as protons, increases at the end of the path forming what 
is known as the Bragg Peak. The depth, of the peaks can be modified in one of two ways:  the 
protons can be accelerated to a different energy, higher or lower, shifting the peak further or closer 
respectively or by introducing a specified thickness of material or specific devices into the beam 
slowing the protons down  thus reducing the range of the beam and possibly changing its shape.  
1.3.4 MODIFICATION OF THE PROTON BEAM 
 
The treatment gantry used for this research at the PTC-H delivers a passively scattered 
beamline, utilizing a double scattering technique. The protons are first accelerated by high RF 
voltage in the synchrotron. Once the selected beam energy is reached, the protons are extracted and 
)(1
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β
π
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delivered to the treatment gantry through the beamline, via a series of proton spills. Once the spill of 
protons arrives at the nozzle of the treatment gantry it can then be modified. A diagram showing the 
path of the beam as it is modified is shown in Figure 1-1. (Sahoo, et al. 2008) 
 
Figure 1.1 Schematic of nozzle components of the passively scattered beams lines at the PTC-H 
utilizing a double scattering technique 
As the proton beam enters the nozzle, it can be shaped using filters and the range can be 
adjusted using a variety of modifiers. A double scattering technique allows the beam to be uniform in 
intensity over the beam’s cross section. As the proton beam hits the first foil scatterer, the beam is 
laterally spread into a Gaussian shape across the beam’s cross section. A second scatterer made of a 
high Z-material with a thickness that varies radially is placed further down the beam path, ensuring 
uniform proton energy, effectively flattening the intensity of the beam. 
For proton therapy treatments, the peak of high dose deposition needs to be enlarged to 
conform to the target volume. This can be achieved using multiple independent peaks to cover the 
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proximal and distal sides of the target volume.  When these peaks are combined they form a spread 
out Bragg peak (SOBP) in a technique called range modulation.  The properties of the SOBP allow a 
level plateau of dose to be deposited at some depth in a patient with a much lower entrance exposure 
and almost no dose after the distal end of the peak.  In contrast, a photon beam will exhibit a higher 
dose towards the end of its path, called the exit dose. This can be seen below in Figure 1-2. 
 
Figure 1.2  Comparison of Percent Depth Dose curves for 10 MV Photons (black line), a series 
of pristine Bragg peaks (blue lines), and a spread out Bragg peak (SOBP) (red lines).  
The production of the SOBP is accomplished by using a called a range modulation wheel 
(RMW), first described by Robert Wilson. (Wilson 1946) The RMW has a series of steps machined 
into a specific material, dependent upon the desired energy of the proton beam, which can be rotated 
at high speeds. The effect of this rotation is that the RMW rapidly changes the range of the beam, 
effectively positioning the Bragg peaks at varying depths. These steps can be seen on a close up 
picture of part of a RMW shown in Figure 1-3. 
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Figure 1.3  Steps on an aluminum range modulation wheel (RMW) used at the PTC-H 
  
The beam, can pass through a series of range shifters, if required, that reduce the range of  
the distal edge of the SOBP to achieve the desired depth. As the protons travel through the air and 
equipment that is located upstream of the patient, the protons suffer repeated elastic coulomb 
scattering. 
The beam is collimated to cover the treatment area using custom designed bronze collimator 
plates, collectively referred to as the aperture. The thickness and number of plates is determined by 
the energy of the treatment beam. An example of one of these plates can be seen in Figure 1-4.  
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Figure 1.4 Bronze collimator plate 
The beam is finally passed through a range compensator. The compensator acts to modify 
the range of the beam such that the distal end of the SOBP conforms to the distal surface of the of the 
target volume. (DeLaney and Kooy 2008) An example of a range compensator made from acrylic is 
shown below in Figure 1-5. 
 
Figure 1.5 Acrylic range compensator 
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The cumulative effect of the scatterers, the RMW, the ranger shifters, the aperture and the 
compensators causes a deflection from the original particle direction and is known as multiple 
coulomb scattering (MCS). To minimize lateral dose fall-off of the beam caused by MCS in air after 
the beam has been effectively flattened, the snout should be manipulated as close to the patient as 
possible, thereby keeping the volume of air between the patient and the snout to a minimum.  
(DeLaney and Kooy 2008) 
1.3.5 RANGE 
The path length of protons determined by both their initial energy and their energy loss as 
they travel through the target material is known as the range of the proton. This range  can be 
calculated using the continuous-slowing-down-approximation (CSDA) which allows a very close 
approximation to the average path length traveled by a charged particle as it slows down to rest. As 
the protons travel along this path, they will lose energy according to the stopping power of the 
material in which they are travelling. In this approximation, the rate of energy loss for all points 
along the track is assumed to be equal to the total stopping power. The CSDA range is obtained by 
integrating the reciprocal of the total stopping power with respect to energy, with units of distance 
travelled per unit energy loss. The individual protons path lengths differ slightly from each other as 
they do not lose the same amount of energy with each interaction. These energy-loss fluctuations of 
the energy imparted by individual protons due to multiple coulomb scatterings are called range 
straggling and neglected in the CDSA. (ICRU 1993)  
Since the range of the proton is directly related to its energy, as the energy of the proton 
beam increases, then penetration depth also increases. A 125MeV proton has a range of 12cm in 
water and a 200MeV proton has a range of 27cm in water. (Wilson 1946) A proton beam composed 
of 160MeV protons has a mean range of 17cm in water. Due to the range straggling mentioned 
above, not all these protons stop at exactly 17cm. Because of the statistics of the multitude of 
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interactions involved, this can result in a approximately a 1% fluctuation of the range. (DeLaney and 
Kooy 2008) 
1.3.6 RELATIVE BIOLOGICAL EFFECTIVENESS 
As radiation from charged particles is absorbed in a biological material, ionization occurs 
and most of the lost energy is deposited to liberated electrons along the track of the charged particles. 
This distribution is characteristic of the particular type or energy of the radiation involved and is also 
dependent upon the energy of the particles. These different particles have different degrees of 
effectiveness when irradiating tissues in biological systems.  The concept of relative biological 
effectiveness (RBE) was developed to compare these radiation sources and describes the amount of 
dose from a radiation source that is needed to produce the same biological effect as a known standard 
source of radiation. (Johns and Cunningham 1983) 
 
RBE=𝐷𝑜𝑠𝑒 𝑓𝑟𝑜𝑚 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑆𝑜𝑢𝑟𝑐𝑒 𝑡𝑜 𝑃𝑟𝑜𝑑𝑢𝑐𝑒 𝐵𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙 𝐸𝑓𝑓𝑒𝑐𝑡
𝐷𝑜𝑠𝑒 𝑓𝑟𝑜𝑚 𝑇𝑒𝑠𝑡 𝑆𝑜𝑢𝑟𝑐𝑒 𝑡𝑜 𝑃𝑟𝑜𝑑𝑢𝑐𝑒 𝐵𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙 𝐸𝑓𝑓𝑒𝑐𝑡  
 
Recently for proton therapy, the accepted value of RBE has been under scrutiny, based 
on whether the calculations were performed on tissues or tissue substitutes related to the 𝛼 𝛽⁄  
ratio of the materials involved. For higher energy protons, the ionization track is wide, causing a 
low LET where the ionization is widely dispersed allowing for tissue repair. As the energy decreases, 
the track narrows, and the LET increases as the ionizations happen much closer together.  However, 
the RBE is not consistent across a pristine Bragg Peak, where the ionization at the very end of 
the distal range is mixed because of range straggling, mentioned above. When multiple peaks 
are overlapped, forming an SOBP, there is a leveling of the RBE, with an increase in RBE 
occurring towards the distal end of the SOBP, most likely due to an increase of the LET. Due to 
this increase in the RBE and LET, the penetration of the beam is actually extended by a few 
Equation 2 
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millimeters. (Paganetti, et al. 2002) For our study, the commonly accepted RBE value of 1.1 that 
was determined in the clinical setting using in-vivo laboratory studies with a standard error of 
0.01 will be utilized. 
1.4 New Insert 
1.4.1 EXISTING THORAX PHANTOM 
The RPC currently uses several different anthropomorphic quality assurance phantoms used 
for site credentialing purposes for sites that participate in NCI sponsored clinical trials.  The RPC 
thorax phantom was initially created for verification of stereotactic body radiation therapy (SBRT) 
procedures for lung tumors.  This phantom was built to simulate actual patient anatomy and when 
used in a photon beam, the reproducibility of the dose delivery to the target was 0.5% and radiation 
field localization was less than 2.5mm. (Followill, et al. 2007) The RPC Thorax phantom consists of 
a main phantom body (referred to from here on as the phantom shell) that is filled with water and has 
materials designed to replicate different organs and a removable imaging/dosimetry insert. The 
phantom shell is shown below in Figure 1-6, where the insert’s location can be seen on the right. 
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Figure 1.6 RPC Thorax Phantom – phantom shell 
The thorax phantom is intended not just to measure results of the radiation treatment, but the 
entire treatment procedure from participating institutions, from CT through planning to treatment. 
Accuracy in simulation and treatment planning are just as critical as accuracy in set-up and treatment 
of the phantom.  Since the phantom is anthropomorphic and mimics the organs and shape of a human 
torso, it offers a realistic simulation and requires a patient equivalent dose calculation to be 
performed. The original imaging/dosimetry insert is comprised of cork, as is the remaining lung 
material in the phantom and is shown below in Figure 1-7 The dosimetry insert also doubles as an 
imaging insert and allows the phantom to be shipped “fully loaded” with film and TLD, eliminating 
possible errors that might be incurred by assembly by non experienced personnel. The film contained 
in the insert verifies the accuracy of the CT simulation and treatment planning systems. The TLD 
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provides verification of the physical dose distribution for the treatment delivery. (Followill, et al. 
2007)  
 
Figure 1.7 Disassembled, original cork lung imaging/dosimetry insert 
It was decided at the start of this project that usage of the thorax phantom as is, was not 
possible due to two main construction issues: lung equivalency of the insert material and air gaps 
around the radiochromic film.   
1.4.2 LUNG EQUIVALENT MATERIAL 
Several lung equivalent materials were evaluated for usage in a proton beam.  The relative 
linear stopping power (RLSP) is defined as the linear stopping power of the phantom material 
relative to water. The RLSP for the phantom material needs to be close to that of the corresponding 
standard human lung tissue for that material to be considered lung equivalent. Several materials 
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including Jelotung wood, and vendor specific lung materials such as The Phantom Laboratory (TPL) 
Lung material and Radiation Measurements Incorporated (RMI) Lung material have RLSP’s from 
0.303 at 135 MeV to 0.404 at 225 MeV.  (Moyers, et al. 2010) The RPC thorax phantom was 
designed using cork as the lung equivalent material. Cork is not easily characterized in a proton 
beam, due to an inhomogeneity of the material caused by the many large air pockets contained 
within the structure. Balsa wood contains micro air pockets within the grain that could potentially 
cause fewer issues with distal edge degradation of the SOBP when compared to cork.  
1.4.3 FILM AND AIR GAPS IN CURRENT INSERT 
Another issue with cork is the difficulty with machining tight tolerances in the insert itself. 
The current insert has slots that house the radiochromic film, as well as multiple air channels created 
from the pin prick straws and the closure screws 
In the current insert there are gaps alongside the film that allow the film to slide into the 
insert. Depending upon the orientation of the film and the beams selected for treatment these gaps 
along the film can introduce errors. Film was placed inside the imaging/dosimetry insert in 3 planes: 
Axial, Coronal, and Sagittal, and compressed to remove air gaps. In a study performed in 2005 using 
GAFChromic® MD-55 film, film gap and response versus orientation was explored. For films 
aligned parallel to the beam, an air gap equivalent to one thickness (0.26mm) of GAFChromic® film 
showed an 18% over response of the film.  When that gap was increased to 3 times the thickness of 
the film (0.78mm), the over response was 22%. When the film was perpendicular to the beam or no 
air gap was present, the difference in response was 3% or less. (Nerbun 2005) This result was 
verified using EBT film by Zhao and Das, where they state that serious artifacts and errors are 
present in the depth dose distributions displayed on film, and that the dose errors increase as the gap 
increases. (Zhao and Das 2010) 
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1.5 Hypothesis and Specific Aims 
The existing RPC heterogeneous thorax phantom can be modified to assess lung tumor 
proton beam therapy procedures involving patient simulation, treatment planning, and treatment 
delivery confirming agreement between the measured dose and calculated dose within 5%/3mm with 
a reproducibility of 5%.  
Selection of phantom materials and design plans were created allowing the existing phantom 
to be utilized in a proton beam. The phantom was then simulated on a CT scanner at the PTC-H, 
planned and treated using clinical techniques to emulate a lung tumor treatment with proton therapy. 
The agreement criteria in the hypothesis were then tested through the completion of the specific aims 
listed below. Throughout the entire process, modifications were made and the specific aims were 
tested and verified. The specific aims to complete this research were: 
1) Determine the equivalency of phantom lung material to the patient anatomy counterpart, and 
modify the existing thorax phantom/insert correspondingly. 
2) Determine the LET dependence of radiochromic film for parallel and perpendicular 
orientation in water. 
3) Image the modified insert and thorax phantom to create clinically relevant treatment plans, 
and irradiate the phantom with these treatment plans. 
4) Measure the delivered dose distribution and the dose to specific points within the irradiated 
thorax phantom and compare the calculated and measured doses and dose distributions to 
determine the deviations and reproducibility. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Phantom Design and Construction 
It was decided to base the lung phantom for protons on the existing RPC Thorax phantom. 
The only change would be to re-design a new dosimetry/imaging insert that would be appropriate for 
use in a proton beam. The material selected would need to be lung density equivalent. Based on long 
accepted research lung density can range from 0.348 g cm3⁄   to 0.193 g cm3⁄  depending on age and 
whether or not the lung tissue is normal or abnormal. (Van Dyk, Keane and Rider 1982) The average 
density of the target material was decided to be approximately 0.300 g cm3⁄  , agreeing with the 
materials evaluated in the Moyers paper, where the average density was in the 0.300-0.400 
g cm3⁄  range. (Moyers, et al. 2010)  
Multiple patient images were examined, including both normal and abnormal lung tissue to 
determine a range of acceptable Hounsfield Units (HU) for the phantom material. The calculation of 
HU is shown below: 
HU = �
𝜇Material − 𝜇Water
𝜇Water
� × 1000 
Based on multiple patient images such as the ones shown in Figure 2-1, it was determined that the 
range of acceptable HU’s was between -300 and -900 depending upon the levels of inflation and 
density of the lungs where the ROI’s were drawn.  
Equation 3 
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Figure 2.1 Random sample of lung patient's CT images 
2.1.1 LUNG INSERT MATERIAL 
To find an equivalent lung material, the material had to have a density similar to the density 
of average lung tissue, and also have a HU number comparable to the average of patient lung tissue. 
Several materials were researched, and based on cost and ability to be machined to tight tolerances, 
extra heavy balsa wood was selected.  Extra heavy balsa is specific type of balsa with a density over 
20 lbs. ft3⁄ . Multiple blocks of balsa stock were ordered, measured and weighed to calculate the 
average density of the sample. The density range of the sample was from 0.300 to 0.340 g cm3⁄ , 
which was deemed acceptable. The samples were then suspended in air and CT’s were performed on 
the blocks using a standard chest protocol on a GE Lightspeed X/Qi CT scanner (GE Healthcare , 
Waukesha, WI) and regions of interest (ROIs) were measured across the different blocks to 
determine the HU numbers of the samples.  A sample image is shown below in Figure 2-2. 
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Figure 2.2 CT Image of balsa block suspended in air 
The HU numbers of the sample ranged from -590 to -790 with a mean of -670, which places 
the material right in the middle of the range of patient numbers discussed in the previous section. 
The balsa was then stored in a climate controlled office with temperature set to 72 degrees 
Fahrenheit to maintain steady moisture content of the wood. 
2.2 Material Relative Linear Stopping Power 
As discussed in Section 1.3.5, protons will lose energy according to the stopping power of 
the material in which they are travelling. This loss of energy is also related to the initial energy and 
the relative linear stopping power (RLSP) of the materials in the beam’s path. Depth dose curves are 
characterized using a water tank and parallel plate chamber for every energy, SOBP, and range 
combination available for each snout size. When a material of different RLSP than water is inserted 
into the tank displacing an equal volume of water, the distal edge of the Bragg peak is shifted either 
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shallower, for materials of RLSP, or deeper, for materials of lower RLSP. The materials for the 
phantom shell were initially designed for usage in photon beams for SBRT, and were characterized 
in proton beams when the RPC commissioned their Pelvis Phantom. (Grant 2010) Two additional 
materials needed to have their RLSP’s measured for this study: cork and balsa. 
2.2.1 DEPTH DOSE SCANNING 
The RPC possesses a portable water tank phantom and scanner that is used for remote site 
visits. This scanner was used to measure the RLSP of both the cork and balsa samples.  The primary 
scanning ion chamber used with this scanner was an Exradin P11 parallel plate chamber (Standard 
Imaging, Middleton, WI). The reference ion chamber, placed in from of the window was an Exradin 
A12 thimble chamber (Standard Imaging, Middleton, WI). The tank was filled with water to a level 
higher than the mylar entrance window of the tank. The proton treatment gantry was then set to 270 
degrees with a source to axis distance of 270 cm to the inside of the mylar window.   
A reference curve of the beam in water was acquired to be used as a baseline for calculating 
the RLSP. A sample of cork that was used to construct the insert was measured with calipers and 
then taped to the front of the window outside of the water tank, and a depth dose curve was acquired. 
The same beam conditions were used for scanning the materials as were used for the reference curve. 
This procedure was then repeated for the balsa sample, shown in Figure 2-3 . 
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Figure 2.3 Balsa sample being scanned for RLSP analysis at PTC-H 
2.2.2 STOPPING POWER ANALYSIS 
Using the average of 5 maximum points located at the beginning of the SOBP, the individual 
curves for both the balsa and the cork were each normalized to to the reference depth dose curve. To 
determine the stopping power, the difference between the reference curve and each material curve at 
the distal 90% points was then calculated.  The formula to calculate the RLSP from this data was 
taken from the Moyer’s paper. (Moyers, et al. 2010) The material was attached to the front of the 
water tank, not displacing any water, as both the cork and balsa are hygroscopic and would absorb 
water if placed in the tank. The RLSP equation is shown below, where R 90,W is the distance to the 
distal 90% point on the reference curve, R 90.m is the distance to the 90% point on the material curve, 
and tm is the thickness of the material.  
RLSP = 
�R90,W − R90, m �
tm
 
 
Equation 4 
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2.3 Construction 
The imaging/dosimetry insert was redesigned to utilize extra heavy balsa and to minimize air 
gaps.  The new insert design was based on a series of tapered wedges that fit into a tapered ring, a 
cross section is shown below in Figure 2-4. 
 
Figure 2.4 Cross section of tapered outer balsa ring 
Two sets of these rings and wedges were utilized; one for each the superior and inferior 
sections of the insert, housing the sagittal and coronal films, and when compressed into the outer hi-
impact polystyrene outer housing, straddle the central axial film slice.  Located at the center of the 
insert, cut into 8 quarter wedges is the hi-impact polystyrene insert that mimics the tumor and is 
assigned the Gross Tumor Volume (GTV) when treatment planned. The tumor inserts and film 
planes can be seen in Figure 2-5. 
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Figure 2.5 Schematic of an individual wedge (left), and half of the wedges shown stacked 
assembled in a wireframe that represents the outer tapered balsa ring (right). The tumor insert 
is shown in white. The colored lines depict the film plane: blue – axial, red – sagittal, yellow – 
coronal.  
The outer housing of the insert has removable end caps that screw closed providing 
compression that laterally tightens all of the wedges together effectively removing the air gap around 
the films.  Before machining, all of the individual balsa blocks were imaged with a CT scanner and 
the only blocks that were close in HU were utilized. After construction, the parts were then 
assembled and imaged again with a CT scanner using the smallest field of view (FOV) possible to 
increase resolution, to verify compression.  All of the parts for the insert are shown below in Figure 
2-6. 
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Figure 2.6 Balsa imaging/dosimetry insert. Assembled inferior wedge and ring shown on the 
right. The sleeve and superior endcap are shown in the back. The individual superior wedges 
and ring are shown in front. 
2.4 Treatment Planning 
The dosimetry/imaging insert was assembled with dummy film and TLD to simulate how the 
insert will be loaded under treatment.  Since the purpose of the RPC lung phantom is to evaluate the 
entire treatment process, care was taken to treat the phantom as a patient would be imaged and 
treated. The outer phantom shell was filled with water, and rocked to remove air bubbles. The balsa 
insert was aligned in the proper orientation and inserted into the outer shell where tape was placed to 
keep it from moving.. The assembled phantom was imaged at the PTC-H on an in-house GE 
Lightspeed RT16 Computed Tomography scanner (GE Healthcare , Waukesha, WI) calibrated for 
proton treatment .  The phantom was placed on the CT table, and after careful alignment of the 
phantom using multiple scout images, the outer shell was marked at the localization laser points with 
pen marks and plastic fiducial BBs were placed at those marks. The BBs were used to verify that the 
phantom was aligned to the set-up lasers as all of the BBs appeared in the same plane. The BBs 
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would later be contoured out when planning the treatment, so as not to add additional material to the 
path of the beam that might affect beam delivery. The protocol used was the free breathing lung 
prescription that is utilized on patients, yielding 2.5mm image slices. Multiple plans were developed 
and evaluated. Plan 1a and Plan 3 were selected, and will be referred to in the remaining portions of 
the paper as Plan 1a and Plan 1b, respectively, to eliminate confusion. 
2.4.1 ECLIPSE 
The treatment planning system (TPS) utilized by the PTC-H to create patient treatment plans 
is Eclipse (Varian Medical Systems, Palo Alto, CA). The TPS utilizes a calibration curve that 
converts the HU from a calibrated CT scanner to relative linear stopping powers that match those of 
human tissue. The CT scan of the lung phantom was uploaded to Eclipse to determine the exact HU 
for each material in the phantom. Profiles were drawn across each balsa wedge, 10 sample points 
were taken for each and averaged together, yielding the HU for balsa. The same was repeated for a 
section of cork in the anterior lung segment on the patient left side of the phantom.  
2.4.2 STOPPING POWER COMPARISON 
Once the HU values of the materials were determined, they were plotted against the 
measured RLSPs as mentioned in section 2.2.2 Stopping Power analysis. These values were then 
plotted on the TPS calibration curve, along with points for PVC, Hi-impact (HI) Polystyrene, and 
Acrylic- PMMA. Traditionally, multiple organ samples were measured to set the points for bone, 
soft tissue, fat, brain matter, etc. Because the ex-vivo lung tissue samples could not be inflated, the 
value for lung tissue had to be estimated, resulting in possible discrepancies of lung tissue density.  
The stopping power curve at densities less than water was determined by drawing a straight line 
from the HU of air (-1000 HU) to the HU of water (0 HU).  The RLSP comparisons were then made 
to validate the new lung insert’s usage in proton therapy, and possibly predict differences between 
treatment plans based on the calibrated curve, and by using points based on measured material 
specific RLSP. 
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2.4.3 TREATMENT PLAN 1A 
The first of two treatment plans to be developed was based on using two orthogonal beams 
set at 0 and 90 degrees, entering the anterior and patient left side of the phantom. It had been noted 
that delivering dose to  film in a phantom where the film is aligned in the parallel orientation can 
introduce errors, possibly due to the protons streaming down the film (which has a different RLSP 
than the surrounding material) or possibly due to air gaps surrounding the film. It was decided to 
develop a plan this way so that the results could be compared with a second plan where the beams 
would not be parallel to the films.  To insure that the beams would be parallel to all of the films, the 
treatment couch was set to a zero degree couch kick, so that the axial films would also be parallel to 
the incident beams. The outer shell was contoured to remove the BBs as mentioned at the beginning 
of Section 2.4. All of the remaining structures in the phantom, including the heart, spine, and right 
lung, were then contoured. The two orthogonal beams as placed, were termed the initial beams, and 
initially formed a tight box around the tumor, or GTV. The range and SOBP were modified to ensure 
smooth coverage on the distal end of the GTV. Since the tumor was not moving, no margins were 
added and the GTV was prescribed to receive 100% of the dose. Also, when treating patients we 
modify both the compensator and the collimator to ensure complete coverage of the GTV.  This is 
accomplished by smearing the milling steps defining the distal edge of the tumor site by 10mm and 
expanding the treatment aperture by 10mm, thereby accounting for any unobserved motion or set up 
errors that might cause the tumor to be slightly off target.  As the purpose of the phantom is to verify 
the treatment planning of a patient, the range compensator was therefore smeared by 6mm, also the 
aperture was expanded by 10mm. (DeLaney and Kooy 2008) This expansion results in a dose 
overshoot on the lateral edges of the treatment field and can be seen in Figure 2-7. The TPS then 
designed the correct apertures and compensators for both fields, and this information was transferred 
to the machine shop at the PTC-H for construction. 
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Figure 2.7 Axial view of treatment plan 1A at isocenter. Both apertures for fields 1 and 2 are 
shown. Notice the overshoot "horns" on the lateral edges of each field. 
Upon approval of the plan, the dose was scaled back from 37 fractions at 200 cGy, giving a 
total dose of 7400cGy,  to 200 cGy at the GTV. This would test the treatment system’s ability to 
deliver a single fraction to the phantom. Three fractions would be utilized to yield a combined dose 
600 cGy.  The beam parameters for plan 1a are shown in Table 1. 
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 Field 1 Field 2 
Nominal 
Energy 140 MeV 160 MeV 
SAD 270 cm 270 cm 
Snout Size 18 cm x 18 cm 18 cm x 18 cm 
Gantry Angle 90 0 
Couch Angle 0 0 
Planned 
Distal Target 
Distance 
8.1 cm 11.9 cm 
Nominal 
SOBP Width 5.0 cm 5.0 cm 
Snout 
Position 30.0 cm 30.0 cm 
Range 
Modulator RM 85 RM 84 
Range  
(Distal 90%) 10.2 cm 13.4 cm 
Range 
Shifter RS 22 RS 16 
Shifted 
distance 2.1 cm 1.5 cm 
GTV dose 101.0 cGy 99.0 cGy 
 
Table 1 Plan 1a Treatment Parameters. Prescribed dose is 200 cGy. 
2.4.4 TREATMENT PLAN 1B 
For the next treatment plan, the gantry angles and couch angles were adjusted to eliminate 
the proton streaming issues. It has been reported that tilt angles of as little as 2 degrees  (Zhao and 
Das 2010) can reduce this effect; however the effect is still present on the distal end of the SOBP. 
Our study utilized a 10 degree tilt angle, with gantry angles of 10 and 80 degrees, comparable to a 
technique in a study that irradiated a film insert that was located near a critical structure (Vatnitsky, 
et al. 1997). The couch was then rotated -15 degrees to 345 degrees.  The two initial beams, as 
placed, formed a tight diamond-shaped dose distribution around GTV. The range and SOBP were 
modified to ensure smooth coverage on the distal end of the GTV, and then the compensator and 
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apertures were modified and smeared the same way as in plan 1a. The beam parameters are shown 
below in Table 2 and the placed field is shown in Figure 2-8 . 
 
Figure 2.8 Axial view of Plan 1b Note the fields have been angles to 10 and 80 degrees. Also 
note that the overshoot "horns" on the lateral edges of each field. 
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 Field 1 Field 2 
Nominal 
Energy 140 MeV 160 MeV 
SAD 270 cm 270 cm 
Snout Size 18 cm x 18 cm 18 cm x 18 cm 
Gantry Angle 80 10 
Couch Angle 345 345 
Planned 
Distal Target 
Distance 
8.1 cm 11.0 cm 
Nominal 
SOBP Width 5.0 cm 5.0 cm 
Snout 
Position 30.0 cm 30.0 cm 
Range 
Modulator RM 85 RM 84 
Range  
(Distal 90%) 10.2 13.4 
Range 
Shifter RS 22 RS 25 
Shifted 
distance 2.1 cm 2.4 cm 
Tumor dose 102.4 cGy 97.6 cGy 
 
Table 2 Plan 1b Treatment Parameters. Prescribed dose is 200 cGy. 
  
2.5 Dosimeters 
Two types of dosimeters were used in to evaluate the irradiation inside the phantom: 
thermoluminescent dosimeters TLD ( Quantaflux, LLC, Dayton, Ohio) and GAFChromic® EBT2 
radiochromic film (International Specialty Products, Wayne, NJ). The TLD allows for the absolute 
dose to be measured at two specific sites in the tumor site in the lung insert. The film dose, once 
calibrations are applied, can then be scaled to this point, thereby allowing for two dimensional (2D) 
profiles to be drawn in each film plane: axial, sagittal, and coronal. 
2.5.1 TLD 
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Thermoluminescent dosimeters (TLDs) utilize trapping centers of varying energies to 
capture electrons that are released by incident radiation from the valence band to the conduction 
band. (Knoll 2000) The TLDs can then be read by exposing the dosimeter to heat, thereby releasing 
the trapped electrons back to the valence band in turn releasing visible light. This light can then be 
read by a photomultiplier tube (PMT), which amplifies and converts the input thermoluminescent 
(TL) signal to a measurable electronic reading. This signal can then be compared to the temperature 
at the time of the light emission and an output glow curve is produced. This glow curve contains 
multiple peaks that correspond to the different energy traps in the TLD. The lower energy traps are 
unreliable as they tend to not be stable at room temperature, releasing their electrons back to the 
valence band using spontaneous recombination. By waiting at least 10 days to read out the TLD, 
most of these traps have already lost their TL signal, and the remaining low energy traps are relieved 
of their electrons by preheating the crystal before the actual reading takes place.  The integrated TL 
signal under the remaining glow curve directly corresponds to the number of photons released. This 
reading, along with several correction factors will give the total absorbed dose delivered to the TLD. 
This is shown below in Equation 5. 
D = T ×𝐾𝐿 × 𝐾𝐸 × 𝐾𝐹 ×  S 
The absorbed dose, D, is calculated by adjusting T, which is the total TL signal divided by 
the mass of the powder, using several factors: 𝐾𝐿, the linearity correction; 𝐾𝐸, the energy correction; 
𝐾𝐹, the fading correction; and S, the sensitivity of the system. The readout of the TLD was 
performed by the RPC. Since these K factors are consistent for each batch of TLD, they are only 
measured and calculated during the commissioning of the batch, in this case Batch 07.  
The K factors are determined using a variety of methods. The linearity correction factor,𝐾𝐿, 
accounts for the supra-linearity response of each individual TLD batch over the range of 1-40Gy. To 
acquire this factor, several TLD capsules are irradiated over the designated range, and a least squares 
Equation 5 
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fit is applied to reading vs. dose curve. This calculation is shown below, using batch specific 
quadratic parameters a,b, and c in Equation 6. 
𝐾𝐿 =  a𝑥2 + b x +c 
The energy correction factor, 𝐾𝐸, is derived by comparing the dose response of the TLD in a 
specific beam to the known response of TLD in a 60Co beam for the same absorbed dose. The fading 
correction factor, 𝐾𝐹, is calculated using the equation shown below, in Equation 7, where the 
parameters a, b, c, d and N are all batch specific, and X is the time (in days) from irradiation. 
𝐾𝐹 = N (a×𝑒−𝑏𝑋 +  𝑐 × 𝑒−𝑑𝑋)⁄  
The system sensitivity, S, can vary from reading session to reading session, and as such is 
calculated at every reading session. These variations can be caused by heater characteristics, 
reflectivity of the heated planchette, and subtle variation sin the readout electronics. (Kirby, Hanson 
and Johnston 1992) The system sensitivity correction factor, S, is shown below in Equation 8, and 
utilized the previously discussed correction factors. The system sensitivity correction factor is 
calculated using standard doses (“standards”) that are read out at the beginning and end of each 
session.  And based on the time point of each reading taken between them, the individual reading 
system sensitivity can be interpolated.  
S= Dstandard (Tstandard × 𝐾𝐹 standard × 𝐾𝐿 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑)⁄  
The TLD used as for this experiment were capsules containing lithium fluoride (LiF) TLD-
100 powder. The capsules utilized were double loaded, which means that there are two separate 
“loads” or aliquots of TLD powder contained in the capsule, each containing  approximately 22 mg 
of powder. These double loads allow for multiple measurements to be taken to improve the readout 
statistics of the final dose measurements.  
Equation 6 
Equation 7 
Equation 8 
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2.5.2 GAFCHROMIC® FILM 
Radiochromic film was used to measure the relative dose distributions of the treatment 
plans. Film is an effective way to gather spatial information in two dimensions, and when calibrated 
and dose adjusted using an absolute dosimeter, such as TLD, the film can give an accurate 
description of the dose distribution. This is accomplished by evaluating the optical density of the 
film, which changes by polymerization within the active layer of the film as a function of the dosage 
received. The radiochromic film used in this study was GAFChromic EBT2 Dosimetry Film (lot 
A06221004, expiration 4343), in the 8” x 10” size.. A schematic of the film is shown below in 
Figure 2-9. (International Specialty Products 2009) 
 
Figure 2.9 Configuration of GAFChromic® EBT2 film 
2.5.2.1 FILM CALIBRATION 
The film was calibrated according to RPC protocol. To reduce uncertainty in our 
measurements, three readings were taken for each irradiation level. To ensure that all film samples 
could be taken from the same piece of film, thereby removing another source of variation, 3 cm by 
6cm sized pieces of film were utilized. These calibration films were then individually placed at 1.5 
cm depth of solid water (dmax for 6MV photons) utilizing a Varian Clinac 600C (Varian Medical 
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Systems, Palo Alto, CA), . An additional 9cm of solid water was placed beneath the calibration films 
on a leveling acrylic block to act as backscatter. The calibration films were progressively irradiated 
from 50 monitor units to 1350 monitor units in a 20 cm by 20 cm field. 
The individual films were then scanned using the RPC’s film scanner, a CCD100 
Microdensitometer by the Photoelectron Corporation (North Billerica, MA). The scanned films were 
exported as X bit .FIT files and analyzed with ImageJ, an open source image analysis software 
developed by the Research Services Branch of the NIH in Bethesda, MA.   
For each irradiation level, the individual films were analyzed for the mean optical density 
over an area approximately 90% of the size of the film to reduce fluctuations caused by possible 
separation of the film along the cut edges.  This was repeated for each film and the average mean 
optical density was recorded for each irradiation level. Since the films were located at Dmax, no 
percent depth dose correction was applied, and the only correction was by multiplying the monitor 
units by the output factor of a 20 cm x 20cm field.  
 
Figure 2.10 Dose response curve of lot# A06221004 GAFChromic EBT2 film; the chart plots 
the optical density against the dose. 
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 To convert the OD of the film to dose, a correction supplied by the inverse of the above 
curve was generated. Per RPC protocols a 3rd order polynomial was generated with an R2= 0.997, 
and is shown below: 
𝐷𝑜𝑠𝑒(𝑂𝐷)  =  38.855(𝑂𝐷3)  −  10.813(𝑂𝐷2)  +  6.1518(𝑂𝐷) 
This calculation was then input into the CERR and utilized to measure the relative dose 
distribution.  These measured distributions were then corrected by the TLD dose and compared to 
the dose maps generated by the Eclipse treatment planning system. 
2.5.2.2 LET DEPENDENCE OF GAFCHROMIC EBT2 FILM 
When looking at an SOBP, the distal-most portion of the dose plateau region contains mostly 
high LET particles, while the more proximal portion of the region contains higher energy, lower LET 
particles. This increase in LET, usually seen in the distal one third of the SOBP, is also directly 
related to an increase in RBE, which is what makes particle beam therapy so effective at cell killing. 
(DeLaney and Kooy 2008)  
2.5.2.2.1 Film Response 
In researching how film responds when used for proton dosimetry, almost every article 
shows an under-response in the area under the Bragg peak. Low energy (less than 6.7MeV) proton 
beam studies were performed on standard EBT film and show that there is an LET quenching effect 
that can be seen in film dosimetry. Two purposed reasons for this are suggested: LET quenching is 
purely due to the single hit detector nature of radiochromic films, or that the quenching of free 
radicals in the film is responsible for this underperformance. (Kirby, et al. 2010) 
2.5.2.2.2 Evaluating film orientation 
There are two ways to orient the film when evaluating the LET dependence of the film: 
parallel or perpendicular. In a recent study, it was shown that when the film is placed in a parallel 
orientation to the beam a 9-18% dose reduction can be seen in the film at the Bragg peak region.  
When the film is placed perpendicular to the beam, the issue of air gaps introducing artifacts and 
Equation 9 
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response changes becomes apparent. To eliminate these air gaps, the film can be tilted up to 10 
degrees. (Zhao and Das 2010) 
To eliminate the effect of air gaps, samples of film were irradiated while submersed in a 
water tank.  These OD values, once plotted were compared to the ion chamber central axis PDD data 
for the exact specific gantry and beam parameters. A bracket was designed and constructed that 
could allow for rotation of 90 degrees, and could be mounted to the stepper motors of the RPC 
travelling water tank, discussed in section 2.2.1.  This bracket is shown with a piece of film prior to 
irradiation in Figure 2-11. 
 
Figure 2.11 GAFChromic film in perpendicular orientation in the RPC portable water tank 
prior to irradiation. 
The film bracket was mounted to the stepper motor of the RPC portable water phantom, and its level 
of plumb was verified using an electronic level, that was zeroed using the patient treatment couch as 
level (in relation to the gantry, at 90 or 270 degrees gantry angle).  For both orientations the tank was 
positioned with isocenter located at the center of the chosen SOBP to initiate a point of reference. 
The bracket was first set to the parallel alignment, with a 2 degree separation between film and beam 
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planes. A long piece of film was inserted and abutted with the inside of the 2mm mylar scanning 
window.  Using the patient alignment lights the film was centered in the beam. This orientation is 
shown below with a piece of film, post irradiation in Figure 2-12. For the perpendicular orientation, 
the film was then zeroed using an alignment bracket, that when combined with the thickness of the 
mylar window gives a known depth. Six depths were then selected, and film was irradiated at each 
location.  The stepper motor was used to move the film to each desired depth.  Vertical alignment 
within the center of the beam was handled using the patient alignment lights from the snout. A 
physical measurement with a ruler was taken to verify accuracy.  
 
Figure 2.12 GAFChromic film in parallel orientation in the RPC portable water tank post 
irradiation. 
After irradiating film at both orientations, the film was scanned using in house software and 
the OD values were measured and compared to acceptance testing depth dose curves for the specific 
gantry/snout combination provided by the PTC-H. 
2.5.3 TREATMENT DELIVERY FOR LUNG INSERT 
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To evaluate treatment delivery of the various treatment plans, the lung insert was loaded 
with TLD and film, inserted into the thorax phantom and placed on the patient treatment table in 
PTC-H Gantry2. The phantom was positioned with lasers, and then alignment was verified using 
orthogonal digital reconstructed radiographs (DRR). Alignment was then evaluated utilizing the 
tumor as the visible marker of interest. Upon verification the apertures and compensators for the first 
field to be treated were installed into the snout and treatment delivery was prepared. The beam 
parameters and the MUs required by the record and verify system were input into the console and the 
phantom was irradiated. This was performed for two fields for each irradiation trial. Both treatment 
plans, Plan 1a and Plan 1b, were irradiated 3 separate times with new film and TLD inserted for each 
trial. The position of the thorax phantom on the treatment couch was noted, and verified after each 
placement of the insert, to ensure no changes to alignment were made.  
2.5.4 TLD AND FILM REGISTRATION 
The irradiated films from each phantom trial were scanned 3 days post irradiation following 
RPC protocols using the CCD100 film scanner.  The 512 by 512 .FIT images generated contain both 
OD values and spatial values, thus allowing them to be overlaid onto a corresponding CT slice or a 
dose map generated by Eclipse.  The phantom insert dimensions were measured from the CT scan of 
the phantom and 5 fiducial points were selected for image registration: The center of the wedges in 
both the superior and inferior ends of the insert, and 3 points on the center slice of the insert, the top 
cylinder wall, left cylinder wall and center of the phantom, which is designated coordinate (0,0,0). 
The TLD coordinates were also designated for each of the 3 scan planes.  
After the film was loaded into the insert, the individual pieces were pricked at known 
coordinates. These locations were verified both with physical measurements and from the CT images 
and along with locations of TLD coordinates and saved for future usage as Proton Lung Phantom 1. 
This data was then input into the in-house analysis software, called RPCFILM, that enables 
registration between the measured dose distribution and the CT exam utilized to generate the 
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treatment plan. This software then integrates with CERR (Computational Environment for 
Radiotherapy Research), and enables the calculated treatment plans to be compared to measured 
dose distribution. (Deasy, Blanco and Clark 2003)  
As mentioned in section 2.1.2, there are 3 planes of film that were analyzed: Sagittal (2 
pieces of film), Coronal (two pieces of film), and Axial (single piece of film). The films from each of 
the irradiated trials were then uploaded by plane and registered using the above mentioned points, 
and the relative dose distribution calculated by the film and TLD compared to the dose maps from 
the TPS. Dose profiles were generated 5mm off center to reduce edge errors that might be introduced 
by the slotting of the film for both the sagittal and coronal planes. The profiles in the sagittal plane 
were drawn in the inferior-superior direction and the anterior posterior direction. The profiles in the 
coronal planes were drawn in the inferior-superior and the left-right planes. The axial film had the 
dose profiles drown through the origin in both the anterior-posterior and left-right planes. 
2.6 Treatment Evaluations 
2.6.1 TLD COMPARISONS 
The TLDs for the phantom trials were read by RPC employees 30 days post irradiation. The 
readings from the TLD session were imported into an Excel spreadsheet and all of the calculations 
previously discussed were used to calculate the measured dose of each trial. This measured value 
was then directly compared to the expected dose at that corresponding point in RPCFILM and a 
correction ratio was applied to the 512 by 512 matrix of OD values on the film, scaling the film to 
match the TLD reading. 
2.6.2 FILM VS. TREATMENT PLAN COMPARISONS 
The delivery of the treatment plan to the phantom was evaluated using two methods: gamma 
analysis and comparison of distance to agreement (DTA) profiles in 2D both utilizing the film data 
and the TPS dose maps. The scanned.FIT images, acquired in section 2.5.4, were loaded into 
RPCFILM. RPCFILM allows the user to select specific settings for the desired phantom. Analysis 
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was based on the selected film plane orientation. Once the desired plane was selected, the physical 
film alignment pricks were registered to known coordinates on the corresponding CT images, by 
selecting the registration points. RPCFILM includes a magnified view pane in the lower right corner 
that enables finer placement of the alignment marks. The magnification window and registration 
points, seen as black X’s overlaid on the film, in a screen capture of RPCFILM shown in Figure 2-13 
below 
 
Figure 2.13 Screen capture of RPCFILM analysis for Plan 1b trial 2 
After registering the measured distribution on the film to the TPS dose maps, the  film 
calibration curve for the specific batch of film used during the irradiation was selected. The 
calibration curve, discussed in section 2.5.2.1, converts the OD of each pixel on the scanned film to a 
physical dose.  The user then inputs the corresponding TLD data, discussed in above in section 2.6.1, 
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normalizing the film dose data to the TLD dose. At this point the user has completed the image 
registration, and both the gamma analysis and the DTA can be performed. 
2.6.2.1 GAMMA ANALYSIS 
Gamma analysis is a tool that can be utilized to determine the accuracy of radiation 
treatment and as such is useful in performing quality assurance of a treatment plan. Gamma analysis 
takes both DTA and percent difference in dosage when comparing planar dose distributions. 
Applying a 2D spatial coordinate system to a dose gradient takes advantage of the complementary 
nature of the dose gradient sensitivities of DTA and percent dose differences. In registering the film 
dose distribution to the Eclipse dose distribution, the gamma analysis allows the percentage dose 
difference and DTA for each pixel to be calculated as components of a vector. The vector is 
normalized to the desired criteria. If the magnitude of this vector at each pixel exceeds 1, then that 
pixel fails the defined criteria (Low, et al. 1998). 
Gamma analysis was performed using CERR and RPCFILM, by selecting the desired 
criteria and running the gamma tool, returning the percentage of pixels passing. At M.D. Anderson, 
for daily IMRT QA we utilize a 5% / 3mm, where the dose distribution assessment will fail the 
gamma analysis if less than 80% of the pixels have magnitudes less than 1. (Childress, et al. 2005) 
The irradiated films will be compared against these gamma-index criteria, 5% dose difference and 
3mm DTA, and is stated in the hypothesis.  However, it is worth noting, that for RPC 
anthropomorphic lung phantoms treated for SBRT using photons, the gamma index criteria are 
5%/5mm, where each film plane must have greater than an 80% pass rate, and the average of the 
planes must be greater than an 85% pass rate.  The irradiated films also will be compared against the 
RPC gamma index criteria to enable a comparison to current anthropomorphic photon quality 
assurance. 
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2.6.2.2 DTA PROFILES 
DTA profiles were acquired 5mm off center on the sagittal and coronal planes to avoid 
artifacts in the OD of the physical dose distribution caused by the slots cut into the film that enables 
them to interlock. The DTA for the axial film was taken directly across the center in both directions, 
as shown below in Table 3. These film profiles were then compared to profiles taken from the 
Eclipse dose distribution using the same coordinates.  
  Start (mm) Stop (mm) 
AXIAL RL Profile (-65,0) (65,0) 
(x,y) AP Profile (0,-65) (0,65) 
CORONAL RL Profile (-65,5) (65,5) 
(x,z) SI Profile (5,-65) (5,-65) 
SAGITTAL AP Profile (-65,5) (65,5) 
(y,z) SI Profile (5,-65) (5,-65) 
Table 3 DTA Profile co-ordinates for Axial, Coronal, and Sagittal films 
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CHAPTER 3: RESULTS AND DISCUSSION 
3.1 Phantom Design and Construction 
3.1.1 MATERIAL RELATIVE LINEAR STOPPING POWERS 
3.1.1.1 RELATIVE LINEAR STOPPING POWER ANALYSIS 
Any material placed into the path of the beam will reduce the range of the protons. The 
materials used for the phantom have different stopping powers than water. For materials of equal 
thicknesses and different stopping powers, the range is affected differently. It is this difference in 
stopping powers that needs to be calculated.  
The depth dose scans for both balsa and cork were obtained with each of the materials 
attached to the outside of the water phantom, and then compared to a depth dose scan of a beam in 
water, as discussed in section 2.2.1. Both the cork and balsa are used to represent tissue in the 
phantom, and needed to be characterized.  The depth dose curve for the balsa is shown in Figure 3-1. 
A similar curve was created for the cork sample. 
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Figure 3.1 Comparison of balsa and reference ion chamber depth dose curves. Note that the 
90% locations are designated with the green X on both curves 
The depth dose curve for both the balsa and cork beams were overlaid onto the depth dose 
curve in water, called the reference curve.  The distal 90% points for both the material curves and the 
reference curve were calculated using a cubic spline interpolation, and are marked on Figure 3-1 
using green “X”’s.  Utilizing the methods and formulas in Section 2.2, for balsa it was determined 
that R 90,W = 191.8mm and  R 90.m  = 185.1mm. The thickness of the balsa sample was determined by 
taking the average of five measurements using calipers at the center of the sample, resulting in  tm = 
20.1mm, with a standard deviation of 0.04 mm, ensuring a uniform sample. Balsa was then 
calculated to have an RLSP = 0.313. The same procedures were repeated for the cork sample, 
yielding an RLSP = 0.227.  
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The RPC utilizes other phantoms made from the same materials as the thorax phantom. For 
the lung phantom, Poly-vinyl chloride (PVC) was utilized in the shell, acrylic was utilized as the 
sleeve into which the imaging/dosimetry insert is placed, high impact (HI) polystyrene was utilized 
as both the shell of the insert and as the tumor target, water fills the phantom body to simulate soft 
tissue, cork is utilized as lung tissue outside of the insert, and balsa is utilized as the lung tissue 
inside the insert. In a previously commissioned RPC anthropomorphic phantom, the RLSP for the 
materials, other than balsa and cork, in the phantom had already been calculated. (Grant 2010) These 
values, including the balsa and cork RLSP’s are shown in Table 4, and the phantom material values 
are plotted against the calibrated values from Eclipse in  Figure 3-2. 
  HU Eclipse SP Phantom 
PVC 800 1.23 
Acrylic 125 1.21 
HI Polystyrene -30 1.07 
Water 17.6 1.00 
Balsa -672.3 0.313 
Cork -690 0.277 
Table 4 Relative stopping linear stopping powers of phantom materials 
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Figure 3.2 Lung Material RLSP-HU chart comparing phantom values to calibrated Eclipse 
curves 
3.1.1.2 STOPPING POWER COMPARISON 
The RLSP for almost all tissues in the human body have been reported previously in 
literature, due to ex vivo scanning techniques. However, lung tissue has not been scanned primarily 
because the tissue cannot show proper levels of inflation in an ex-vivo sample. Most treatment 
planning systems, including Eclipse, create a linear plot from air to the first known tissue sample, 
and place the RLSP for lung tissue at some predetermined HU number along this line. For Eclipse 
this is placed at -739.1 HU, giving a RLSP of 0.258. Previous studies compared different lung 
equivalent materials, both natural and man-made, to determine an effective phantom equivalent 
RLSP for lung tissue. In Table 5 , three different materials had depth dose curves taken at three 
different energies to determine RLSP. (Moyers, et al. 2010)  
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Material  PD ( g/cm3)  HU3  135Mev 
RLSP  
175Mev 
RLSP  
225Mev 
RLSP 
TPL Lung 0.307 -679 0.303 0.305 0.305 
RMI Lung 0.342 -655 0.35 0.337 0.345 
Jelutong 
Wood  
0.429 -580 0.4 0.402 0.404 
Table 5 Relative linear stopping power of three lung equivalent lung materials 
The three materials show very little difference in calculated RLSP based on energy, thus 
proving that each material is relatively energy independent, with the RMI Lung fluctuating the most. 
The extra heavy balsa utilized in the project has a measured density ranging from 0.30 to 0.34 g cm3⁄ , and an average HU of -672.3. The stopping powers were compared to these literature values, 
and when compared to the TPL lung, the difference in HU and RLSP were 0.99% and -2.85% 
respectively. For RMI lung, the differences in HU and RLSP were -2.64% and 9.01%.  For the only 
natural material on the list, Jelutong wood, the differences in HU and RLSP were -15.91% and 
22.14%.  Based on these comparisons and taking into account the cost and availability of the 
materials, it was determined that balsa would be an acceptable material to utilize in a lung phantom. 
3.1.2 COMPRESSION 
After construction of the imaging/dosimetry insert was completed, the removal of air gaps 
via a compression technique needed to be verified. The insert consists of a series of tapered wedges 
inserted into a corresponding tapered ring. When indexed into the HI poly shell, the end caps apply 
pressure squeezing the wedges into the rings, and providing lateral compression, that removes the air 
gaps near the film channels. The insert was placed on a GE Lightspeed X/Qi CT scanner (GE 
Healthcare , Waukesha, WI) and utilizing an HQ pitch with a DFOV = 18.3cm, yielded a resolution 
of 0.35 mm pixel⁄ , shown in .  The profiles across the film channels were then compared and if more 
than one pixel of gap was observed between the film and the insert, the insert was recompressed and 
shot again. It was determined that one wedge set needed to be re-machined, as it could not remove 
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the gap sufficiently. Upon re-machining, it passed visual inspection verifying that the compression 
technique was adequate to remove air gap.  
 
Figure 3.3 High resolution CT scan of imaging/dosimetry insert 
3.1.3 COMPARISON OF PLANS  
Due to the large difference of the PVC material RLSP when compared to the RLSP of a 
similar HU number on the calibrated Eclipse curve, a separate plan was created with the PVC shell 
contoured. A comparison of this new plan to the standard plan would help to evaluate differences, if 
any, which might appear in the treatment of the phantom.  The body of the phantom was contoured 
and a HU of 427.3 was selected based on the measured RLSP of PVC.  There is a tapering of the 
PVC shell in the treatment area which introduces a partial volume effect. A profile was drawn across 
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the shell and the HU for PVC was set for 80% of that profile, placing the shell closer to the 
calibrated Eclipse RLSP curve. To ensure that there would be no differences due to physical 
modifiers of the beam; neither the compensator nor the aperture was modified for the new plan.  The 
beam conditions were then calculated in Eclipse, and the results did not differ from those reported in 
sections 2.4.3  and 2.4.4. From here forward, the unmodified original version of each plan will be 
known as Std. Plan, and the modified versions of each plan will be the PVC Contoured Plan.  Using 
CERR, gamma analysis was performed on the Std. Plan vs. the PVC Contoured Plan, for the axial, 
sagittal and coronal planes, shown below. 
 
Figure 3.4 Gamma analysis of Std. Plan and PVC contoured plan in the axial plane. Gamma 
criteria were set to 5%/3mm 
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Figure 3.5 Gamma analysis of Std. Plan and PVC contoured plan in the coronal plane. Gamma 
criteria is set to 5%/3mm 
 
Figure 3.6 Gamma analysis of Std. Plan and PVC contoured plan in the sagittal plane. Gamma 
criteria is set to 5%/3mm 
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It is worth noting that at the criteria of 5%/3mm, a 100% pass rate was observed, with no 
pixels having a gamma value greater than 1; and therefore no pixels fail the comparison. This would 
lead us to believe that there would be little if any difference when comparing the treated film to the 
different contoured plans, as minimal error will be introduced that will be larger than the 5%/3mm 
criteria. 
3.2 LET Dependence of GAFChromic Film 
The possibility of LET dependence of the EBT2 film based on orientation, parallel or 
perpendicular might cause differences in comparison of 2D dose using film in the insert.  
3.2.1 PARALLEL FILM ORIENTATION 
Artifacts can arise when the film is placed directly parallel to the beam,  so the film for the 
first part of this section was placed at a 2 degree declination to the beam to help reduce this effect. 
This was achieved by placing the gantry at 272degrees and the film horizontally at 270 degrees. 
After irradiation, the film was scanned in house utilizing RPCFILM. Five profiles of the OD were 
taken across the film and averaged.. The OD values were compared to acceptance testing depth dose 
curves provided by the PTC-H.  The two curves were normalized at 6cm and are shown below in 
Figure 3-7 . 
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Figure 3.7 Comparison of depth dose curves obtained using parallel GafChromic EBT2 film to 
depth dose curve obtained with ion chamber from PTC-H at 140 MeV 
The result for this scan showed a large disparity between the two sets of data at the distal end 
of the SOBP.  There were many beam tuning issues, and it was decided that a second method should 
be tried.  For this method placing the gantry at 270 degrees and the film bracket at 268 degrees 
would yield the same angular difference in the orientation of the film and the beam. However the 
beam selected was set to a 5cm SOBP. This should not affect the distal end of the SOBP as the range 
was not modified for either trial using a range modifier, and the energy was set to the same value. 
Both curves were once again normalized at 6cm.  The results for this can be seen below in Figure 
3-8. 
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Figure 3.8 Comparison of depth dose curves obtained using alternate method of  parallel 
GafChromic EBT2 film to depth dose curve obtained with ion chamber from PTC-H at 140 
MeV 
The appearance of this curve more closely resembled that as seen in the literature (Zhao and 
Das 2010).  The percentage difference between the original method and the ion chamber showed an 
average percentage difference between measured points of 55.4% with a maximum difference of 
97.2% at 10.3cm depth. For the alternate method, the average percentage difference of the measured 
points was 31.0% with a max difference of 54.83% at 10.3cm depth. These results are shown in 
Table 6. 
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   Alternate Method Original Method 
Depth  
(cm) 
Ion 
Chamber 
268 Deg. 
Film  
% 
Difference 
270 Deg. 
Film 
% 
Difference 
5.3 0.995 0.984 1.11% 0.947 4.82% 
8.5 1.016 0.948 6.69% 0.949 6.59% 
9.6 1.027 0.829 19.28% 0.707 31.16% 
9.8 1.034 0.747 27.76% 0.424 58.99% 
10.1 0.846 0.393 53.55% 0.059 93.03% 
10.2 0.579 0.267 53.89% 0.025 95.68% 
10.3 0.321 0.145 54.83% 0.009 97.20% 
Table 6 Comparison of Parallel film methods to Ion chamber readings 
3.2.2 PERPENDICULAR FILM ORIENTATION 
After irradiation in the perpendicular orientation, the film was once again scanned and 
analyzed. A linear fit was placed between the 5.3 and 8.5cm points to determine a 6.0cm depth 
value. At this point the film data was then normalized to the ion chamber data. The results are shown 
in Figure 3-9 . The film values at the distal end once again under performed, with an average 
percentage difference of 14.7%, with a max percentage difference of 55.1% at 10.3cm, shown in 
Table 7.   
  Perpendicular Film 
Depth 
(cm) 
Ion 
Chamber Film 
% 
Difference 
5.3 0.995 0.992 0.30% 
8.5 1.016 1.027 -1.08% 
9.6 1.027 0.999 2.73% 
9.8 1.034 0.977 5.51% 
10.1 0.846 0.631 25.41% 
10.3 0.321 0.144 55.14% 
Table 7  Comparison of Perpendicular film method to Ion chamber readings 
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Figure 3.9 Comparison of depth dose curves obtained using ion chamber and perpendicular 
GAFChromic EBT2 film at140 MeV 
Based on these results, it is to be expected that there will be some type of distal edge LET 
effect on the film independent of orientation, with more severe effects seen when the film is closer to 
parallel to the beam path. 
3.3 Phantom Irradiation Evaluation 
Post irradiation, each of the film sets and TLD sets were then prepared to be analyzed. The 
TLD was read out by staff at the RPC 30 days post irradiation, and the film was scanned using an in-
house scanner to acquire .FIT images for evaluation. 
3.3.1 TLD 
The TLD utilized for this project is known internally at the RPC as Batch 07, or B07, and 
had been commissioned by the RPC prior to the start of this project. For this specific batch of TLD, 
the following constants are utilized in the formulas from section 2.5.1. 
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X Days Post Irradiation 
N 1.3493 
A 1.2815 
B 0.00010885 
C 0.06781 
D 0.071908 
Linearity a 2.29840E-08 
Linearity b -2.1190.E-04 
Linearity c 1.0615 
Table 8 TLD formula constants for B07 
3.3.1.1 TLD COMPARISONS 
The TLD capsules used contained two loads of TLD-100 powder. Each load is weighed and 
measured at the RPC, and the two readings for each capsule are averaged together to equal dose at 
the point of measurement.  A comparison of the TLD measurements was made for each trial to the 
calculated beam data from Eclipse over the contoured volume of each TLD. The TLD data for Plan 
1a is shown below in Table 9. The ratios of measured to calculated dose rate indicate that all TLD 
readings were within 6%, except for trial 3 superior which was under 7%.  
 
Calculated 
dose (cGy) 
Measured dose 
(cGy ) 
Measured/ 
Calculated 
dose  Eclipse TLD 
 Plan 1a Trial 1 
PTV Superior 
TLD 
624.4 591.0 0.947 
PTV Inferior  
TLD 
617.9 584.1 0.945 
 Plan 1a Trial 2 
PTV Superior 
TLD 
624.4 590.0 0.945 
PTV Inferior  
TLD 
617.9 584.4 0.946 
 Plan 1a Trial 3 
PTV Superior 
TLD 
624.4 584.6 0.936 
PTV Inferior  
TLD 
617.9 590.1 0.955 
Table 9 Plan 1a TLD dosimetry data 
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The ratios of the TLD data for Plan 1b were then calculated. These are shown in Table 10. It 
should be noted that there was no PTV superior TLD data for trial 1, as there were problems with the 
readout at the RPC.  The ratios of the remaining measured to the calculated doses were all under 6%.   
For the plan 1b trials, the average ratio of the dose rates is 5.4%. 
 
Calculated 
dose  (cGy ) 
Measured 
dose  
(cGy ) 
Measured/ 
Calculated 
dose  Eclipse TLD 
 Plan 1b Trial 1 
PTV Superior 
TLD 624.5 n/a n/a 
PTV Inferior  
TLD 625.3 591.0 0.945 
 Plan 1b Trial 2 
PTV Superior 
TLD 624.5 595.6 0.954 
PTV Inferior  
TLD 625.3 592.6 0.948 
 Plan 1b Trial 3 
PTV Superior 
TLD 624.5 587.7 0.941 
PTV Inferior  
TLD 625.3 589.9 0.943 
Table 10 Plan 1b TLD dosimetry data 
 
The TLD results for the 3 trials in Plan 1a and Plan 1b were then averaged and the standard 
deviation of the 3 trials for each plan was also calculated.  Utilizing the average and the standard 
deviation together allows the calculation of the coefficient of variation (CV) between the trials.  The 
CV is unit less, and therefore allows for comparisons between variables. If a variable has a smaller 
CV then it tends to be less dispersed than a variable with a large CV. (UCLA: Academic Technology 
Services n.d.)For Plan 1a, the CV is less than 1%, indicating that there is very little spread amongst 
the values, shown in Table 11. For Plan 1b, even with only two data points for the PTV superior 
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TLD, the CV is still less than 1%, indicating that there is very little spread amongst the values, 
shown in Table 12 Plan 1b TLD average, Std. deviation, and CV for 3 trials. This reproducibility of 
the phantom measurements means that the phantom design can be utilized as an accurate dosimetry 
device. 
Plan 1a PTV Superior 
TLD 
PTV Inferior  
TLD 
Calculated dose (cGy) 624.4 617.9 
Measured dose 
Average (cGy) 
588.5 586.2 
Std. Deviation 3.44 3.15 
CV 0.58% 0.54% 
Measured Avg. dose/ 
Calculated dose 
0.948 0.949 
Table 11 Plan 1a TLD average, Std. Deviation and CV  for 3 trials 
Plan 1b PTV Superior 
TLD 
PTV Inferior  
TLD 
 
Calculated dose (cGy ) 624.5 625.3 
Measured dose 
Average (cGy ) 
591.65 586.2 
Std. Deviation 5.59 1.4 
CV 0.94% 0.24% 
Measured Avg. dose/ 
Calculated dose 
0.947 0.937 
Table 12 Plan 1b TLD average, Std. deviation, and CV for 3 trials 
Applying a one sample t-test data on the TLD data enables us to check for statistical 
significance of the results. Excluding the Plan 1b Superior TLD (which only had 2 sample points), 
the values for the two-tailed p-value all were less than 0.05 (p<0.05), and therefore are deemed 
statistically significant. 
 
 
 58 
 
3.3.2 CT TO ECLIPSE REGISTRATION 
Before any analysis could be performed the computed tomography (CT) image set needed to 
be registered in CERR to the dose map exported from Eclipse.  The image set was registered using 
2.5mm CT slices. A series of five landmarks with coordinates shown in Table 13 was utilized to 
align and register the images, as they are easily visible and results through multiple registrations 
have proven to be consistent. The first point was selected in the center of the phantom (easily seen by 
the film cross slot) at the superior edge of the insert wedges. The next three points selected were 
located at the center of the phantom insert, with two points on the left balsa cylinder wall and top 
cylinder wall. The center of the film slots was then selected to be the origin (0,0,0) of the entire dose 
map. The final location selected was the center of the phantom at thin inferior end of the balsa 
wedges. After selecting these points for registration, the dose map was aligned to the CT images, and 
the TLD doses were located and compared to the exact doses for the corresponding locations in the 
eclipse dose plan. 
 
edge wedge 
superior 
left 
cylinder 
wall center 
top cylinder 
wall 
edge wedge 
inferior 
x 0 63 0 0 0 
y 0 0 0 63 0 
z -92.4 0 0 0 80.1 
Table 13 CT registration landmarks 
The five landmarks are then evaluated using the root mean square (RMS) value of the 
differences between the listed coordinates and the measurements of the pixels on the CT image. This 
is called the 3D RMS, since all three planes are registered together. For this project a passing value 
of 3D RMS was to be below 1mm, and all registrations complied. The resulting coordinate system 
obtained from this registration can then be utilized by RPCFILM to register and analyze the 2D film 
data.  
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3.3.3 TLD REGISTRATION 
Once the calculated eclipse dose map has been registered to the CT image set, the TLD can 
then be registered to points on the eclipse dose maps. This is accomplished by selecting the physical 
location of the TLD as input into RPCFILM by a table in a reference spreadsheet. The values 
correspond locally to specific dose points on the scanned film images, shown in Table 14, and 
thereby allow for the calibration of the 2D film dose map to a physical dose that can be directly 
compared to the Eclipse calculated dose.  
 Axial Coronal Sagittal 
 
inferior 
TLD 
superior 
TLD 
inferior 
TLD 
superior 
TLD 
inferior 
TLD 
X -4 -4 -4 0 0 
Y 4 0 0 4 4 
Z 0 5 -5 5 -5 
Table 14 Table of TLD physical registration locations for RPCFILM, in mm 
 
3.3.4 FILM SCANNING AND REGISTRATION 
Using our in-house film scanner, the separate pieces of film were then aligned based on 
plane and scanned to .FIT files.  For each trial and specific plane, the .FIT images were uploaded 
into RPCFILM. Each of these “plane” images was then registered to the treatment plan as discussed 
in section 2.5.4. The coordinates of each of the alignment pricks are shown in Table 15. Any errors 
in the alignment would be seen as a shift in the DTA profiles, as the eclipse dose and the film dose 
would not overlay as there would be a misalignment of the physical prick location to the referenced 
coordinates when the phantom was registered using CERR. An example of each “plane” image with 
image registration pricks can be seen in Figure 3-10. From this point both gamma analysis and DTA 
profiles could be acquired by comparing the registered film data to the dose map calculated by 
Eclipse. 
 60 
 
Axial 
  upper right lower left 
x 29 -12 
y 32 -43 
z 0 0 
Sagittal 
  
inferior 
anterior 
inferior 
posterior 
superior 
anterior 
superior 
posterior 
x 0 0 0 0 
y 41 -42 42.5 -41.5 
z 65 75.5 -75 -70 
Coronal 
  
inferior 
right inferior left 
superior 
right superior left 
x 40 -43 44 -40 
y 0 0 0 0 
z 75 70 -65 -74.5 
Table 15 Film registration prick locations 
 
 
Figure 3.10 Plan 1b trial 2 film prick localizers for three separate .FIT “plane” images: a) axial 
image, b) coronal image, and c) sagittal image as seen in RPCFILM 
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3.3.5 GAMMA ANALYSIS 
Gamma analysis was performed on the film from each trial to verify that the agreement of 
the measured and calculated dose. Axial, sagittal, and coronal film sets for each plan and trial set 
were scanned in and analyzed as discussed in Section 2.6.2.  As discussed the software utilized to 
analyze the images is CERR and RPCFILM.  The pass/fail rate for each of the gamma maps is 
shown in the following sections. These rates are color coded and every point with a gamma greater 
than 1 will fail the gamma criteria for that test. The percentage passing is listed and shown in a pie 
chart on the upper right side of the gamma image. The gamma criteria for photon lung phantom 
treatment for SBRT was agreed upon to be 5%/5mm where each plane must pass with an 80% pass 
rate, with the average of all 3 planes greater than 85%.  The gamma criteria proposed in the 
hypothesis was set to 5%/3mm, but since no previous data had been recorded, the pass criteria for 
each film plane and for the total film average was not determined.  The films for each trial were 
analyzed utilizing both criteria sets, and pass rates for 5%/3mm criteria for protons will be 
determined.   The analysis will be shown below for Plan 1a Trial 2 and for Plan 1b Trial 2, with the 
remaining trials being listed in the appendix. 
3.3.5.1 GAMMA ANALYSIS UTILIZING 5%/3MM GAMMA CRITERIA STANDARD PLAN 
The gamma analysis for this section is performed utilizing the 5%/3mm criteria on the Std. 
Plan. The analysis for Plan 1a shows that a large percentage of pixels are failing the gamma criteria, 
and thus agreement between the measured and calculated dose is very low. Based on the literature, 
this result is what was expected. The film planes for all 3 planes were directly in line with treatment  
fields 1 and  2, and although there was no air gap, protons streaming down the film plane were 
expected to produce errors in the distal end of the SOBP due to the distal edge LET effect discussed 
in Section 3.2. Another possible explanation could be distal edge degradation due to Multiple 
Coulomb Scattering (MCS) that occur in the inhomogenieties of the phantom materials. (Urie, et al. 
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1986), (Sawakuchi, et al. 2008)   The gamma analysis results for Plan 1b shows an improvement 
over Plan 1a, with the most significant difference being seen in the axial film plane. These results are 
shown below in Table 16, and the screen captures of the gamma analysis are shown in Sections 
3.3.5.1.1 and3.3.5.5.1.2. In looking at the gamma maps, a majority of the pixels that fail are at the far 
distal end of the SOBP, where the dose has already begun to drop off. It is also worth noting that 
since the treatment plans were based on clinical patient protocols, as discussed in Section 2.4.1, that 
a large majority of the failing pixels occur in the region, the so called “dose horns,” caused by the 
expansion of the aperture and by the smearing of the compensator.  
 Plan 1a Plan 1b 
 Trial 1 Trial 2 Trial 3 Average Trial 1 Trial 2 Trial 3 Average 
Axial 56.13 56.41 53.83 55.46 66.84 74.65 76.15 72.55 
Coronal 75.39 69.76 80.98 75.38 82.17 76.18 77.28 78.54 
Sagittal 77.82 82.45 76.81 79.03 75.21 81.93 73.86 77.00 
3P- 
Average 69.78 69.54 70.54 69.95 74.74 77.59 75.76 76.03 
Table 16 Gamma analysis results for Plans 1a and 1b utilizing a 5%/3mm criteria (displayed in 
percentage passing) 
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3.3.5.1.1 Plan 1a 
 
Figure 3.11 Plan 1a Trial 2 Axial Gamma Analysis 
 
Figure 3.12 Plan 1a Trial 2 Coronal Gamma Analysis 
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Figure 3.13 Plan 1a Trial 2 Sagittal Gamma Analysis 
3.3.5.1.2 Plan 1b 
 
Figure 3.14 Plan 1b Trial 2 Axial Gamma Analysis 
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Figure 3.15 Plan 1b Trial 2 Coronal Gamma Analysis 
 
Figure 3.16 Plan 1b Trial 2 Sagittal Gamma Analysis 
  
 66 
 
3.3.5.2 GAMMA ANALYSIS UTILIZING 5%/3MM GAMMA CRITERIA PVC CONTOURED 
The gamma analysis for this section is performed utilizing the 5%/3mm criteria on the PVC 
Contoured Plan. Due to the large shift on the RLSP of the PVC shell as compared to the standard 
Eclipse curve, gamma analysis was performed to see if any difference would be seen from the Std. 
plan. The analysis for both Plan 1a and Plan 1b still show that a large percentage of pixels are failing 
the gamma criteria and no real statistical difference between the contoured and standard plans are 
visible. This result was surmised in Section 3.1.1, where the comparison of the calculated dose plans 
yielded very little difference from what was expected. Once again, the gamma analysis results for 
Plan 1b show an improvement over Plan 1a, with the most significant difference being seen in the 
axial film plane. These results are shown below in Table 17, and the screen captures of the gamma 
analysis are shown in Sections 3.3.5.2.1 and 3.3.5.2.2. 
 Plan 1a Plan 1b 
 Trial 1 Trial 2 Trial 3 Average Trial 1 Trial 2 Trial 3 Average 
Axial 55.56 59.72 55.56 56.95 65.59 74.16 75.80 71.85 
Coronal 74.41 69.04 80.81 74.75 82.37 75.60 76.46 78.14 
Sagittal 78.56 83.89 77.69 80.05 75.52 82.49 73.94 77.32 
3P- 
Average 69.51 70.88 71.35 70.58 74.49 77.42 75.40 75.77 
Table 17 Gamma analysis results for Plans 1a and 1b utilizing a 5%/3mm criteria (displayed in 
percentage passing) and a PVC contoured shell. 
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3.3.5.2.1 Plan 1a – PVC contoured 
 
 
Figure 3.17 Plan 1a Trial 2 Axial Gamma Analysis with PVC Shell contoured and CT Number 
set to match Eclipse Calibration Curve 
 
Figure 3.18 Plan 1a Trial 2 Coronal Gamma Analysis with PVC Shell contoured and CT 
Number set to match Eclipse Calibration Curve 
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Figure 3.19 Plan 1a Trial 2 Sagittal Gamma Analysis with PVC Shell contoured and CT 
Number set to match Eclipse Calibration Curve 
3.3.5.2.2 Plan 1b- PVC Contoured 
 
Figure 3.20 Plan 1b Trial 2 Axial Gamma Analysis with PVC Shell contoured and CT Number 
set to match Eclipse Calibration Curve 
 69 
 
 
Figure 3.21 Plan 1b Trial 2 Coronal Gamma Analysis with PVC Shell contoured and CT 
Number set to match Eclipse Calibration Curve 
 
Figure 3.22 Plan 1b Trial 2 Sagittal Gamma Analysis with PVC Shell contoured and CT 
Number set to match Eclipse Calibration Curve 
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3.3.5.3 GAMMA ANALYSIS UTILIZING 5%/5MM GAMMA CRITERIA STANDARD PLAN 
The gamma analysis for this section is performed utilizing the RPC guidelines of   5%/5mm 
criteria with 80% individual plane pass criteria, and 85% overall pass criteria, that are based on 
recommendations of the RTOG. Due to the results from the previous section, only the Std. Plan was 
analyzed using these criteria, as the contouring of the PVC shell did not introduce any significant 
improvements to the gamma analysis. The analysis for both Plan 1a and Plan 1b show a much higher 
percentage of pixels are now passing the gamma criteria, as to be expected with a change of the DTA 
from 3mm to 5mm.  The gamma analysis results for Plan 1b show an improvement over Plan 1a, 
with the most significant differences being seen in the axial plane with up to a 14.02% improvement.  
Following the pass criteria set forth by the RPC, all 3 trials for Plan 1b would be classified as 
passing, by a wide margin. These results are shown below in Table 18, and the screen captures of the 
gamma analysis are shown in Sections 3.3.5.3.1 and 3.3.5.3.2. 
 
 Plan 1a Plan 1b 
 Trial 1 Trial 2 Trial 3 Average Trial 1 Trial 2 Trial 3 Average 
Axial 73.56 74.70 72.51 73.59 85.70 87.95 86.53 86.73 
Coronal 86.64 84.41 90.45 87.17 92.21 88.68 89.01 89.97 
Sagittal 91.03 92.81 88.50 90.78 89.00 93.11 88.26 90.12 
3P- 
Average 83.74 83.97 83.82 83.85 88.97 89.91 87.93 88.94 
Table 18 Gamma analysis results for Plans 1a and 1b utilizing a 5%/5mm criteria (displayed in 
percentage passing)as established by the RPC based on RTOG recommendations. 
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3.3.5.3.1 Plan 1a  
 
Figure 3.23 Plan 1a Trial 2 Axial Gamma Analysis 5%/5mm 
 
Figure 3.24 Plan 1a Trial 2 Coronal Gamma Analysis 5%/5mm 
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Figure 3.25 Plan 1a Trial 2 Sagittal Gamma Analysis 5%/5mm 
3.3.5.3.2 Plan 1b 
 
 
Figure 3.26 Plan 1b Trial 2 Axial Gamma Analysis 5%/5mm 
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Figure 3.27 Plan 1b Trial 2 Coronal Gamma Analysis 5%/5mm 
 
Figure 3.28 Plan 1b Trial 2 Sagittal Gamma Analysis 5%/5mm 
3.3.6 DTA PROFILE COMPARISONS 
As the gamma analysis takes into account all pixels over the desired area, including the extra 
dose “horns,”   dose profiles were taken through the central region of the tumor target for all plans 
and then compared to the corresponding TPS data. A linear regression was applied to the sides of 
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each profile to calculate the distance to agreement of the film to the TPS. Due to the complex nature 
of the beams the dose levels from which the regression was applied varied both by plan, film plane, 
and profile direction. These values are shown in Table 19.  
    Plan 1a Plan 1b 
Axial  Right Left Profile 
  Patient Right  80%-30% 80%-20% 
  Patient Left 80%-60% 80%-60% 
  Anterior Posterior Profile 
 Posterior 80%-40% 80%-20% 
  Anterior 80%-60% 80%-60% 
Coronal Right Left Profile 
  Patient Right  80%-30% 
80%-20% 
  Patient Left 80%-60% 
  Superior   Inferior Profile 
 Superior 
80%-20% 80%-20% 
  Inferior 
Sagittal Anterior Posterior Profile     
  Posterior 80%-40% 80%-20% 
  Anterior  80%-50% 80%-50% 
 Superior Inferior Profile     
 Superior 
80%-20% 80%-20% 
 Inferior 
Table 19 Dose levels for linear regressions utilized to calculate DTA 
For the following DTA figures, the profile taken from the Eclipse TPS with be shown in blue 
and designated TPS on the graphs. The Film data will be shown in red and is designated film dose on 
the graphs.  Some of the film curves will show a drop at the origin, which is related to the film slots 
being cut into the film in the sagittal and coronal films that slows them to interlock, and therefore no 
dose was recorded in that region. 
3.3.6.1 PLAN 1A 
Treatment Plan 1a trial 2 had all 3 film planes analyzed for DTA.  The first film analyzed is 
the axial film. Both the Anterior posterior and right left profiles are directly in parallel with the beam 
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with the entrance of the beam coming from the anterior side and the patient left side.  Looking at the 
Anterior Posterior profile, Figure 3-29, first reveals that there is a 4.9mm average distance over the 
specified dose levels on the posterior side of the profile, which corresponds to the distal end of the 
beam. In Figure 3-30, the Right left profile shows an average of 5.8mm difference over the dose 
levels on the distal end of the treatment beam.   
 
Figure 3.29 Plan 1a Trial 2 Anterior Posterior Profile Axial Plane 
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Figure 3.30 Plan 1a Trial 2 Right Left Profile Axial Plane 
Depending on the complexity of the interfaces and the position of the detector, the distal edge 
differences could range from 2mm to 8mm at 80% dose levels (Urie, et al. 1986). Compounding this 
with the LET effect on the distal edge of the film, and with the protons streaming directly down the 
film plane, these DTA’s were expected to be large.  
The profiles drawn across the Coronal planes can be seen in Figure 3-31 and Figure 3-32. for 
the Coronal plane the superior inferior direction is not directly oriented with the beam path, and 
therefore no real degradation due to LET or Distal edge degradation  should be seen. The DTA for 
the superior and inferior sides are 1.6 and 1.1mm respectively. The Right left profile, which is in line 
with one of the treatment fields once again shows a larger DTA with 2.0mm on the patient right side, 
which corresponds with the distal edge of the beam. 
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Figure 3.31 Plan 1a Trial 2 Superior Inferior Profile Coronal Plane 
 
Figure 3.32 Plan 1a Trial 2 Right Left Profile Coronal Plane 
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The sagittal films are very similar to the coronal films. The anterior posterior profile, Figure 
3-33, which is in line with  one of the treatment fields, showed a DTA of 2.5mm on the posterior 
(distal) end of the beam, where the superior and inferior sides of  Figure 3-34 are 1.2mm and 1.0mm 
respectively.  The remaining DTA analysis for the other two trials of Plan 1a, as well as a summary 
of the DTA results, is located in the appendix. 
 
Figure 3.33 Plan 1a Trial 2 Anterior Posterior Profile Sagittal Plane 
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Figure 3.34 Plan 1a Trial 2 Superior Inferior Profile Sagittal Plane 
Comparing the averages of the three trials, and utilizing the pass fail criteria of 3mm from 
the hypothesis, the only failing points come from the distal ends of the axial film profiles, shown 
below in red in Table 20 Plan 1a DTA data averaged over 3 trials. 
Plan 1a DTA Averages 
Axial  Right Left Profile Anterior Posterior Profile 
  Patient Right  5.3 Posterior 5.6 
  Patient Left 1.2 Anterior 0.2 
Coronal Right Left Profile Superior Inferior Profile 
  Patient Right  1.5 Superior 1.3 
  Patient Left 0.6 Inferior 1.1 
Sagittal Anterior Posterior Profile Superior Inferior Profile 
  Posterior 2.0 Superior 1.0 
  Anterior  0.9 Inferior 1.4 
Table 20 Plan 1a DTA data averaged over 3 trials 
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3.3.6.2 PLAN 1B 
The same DTA analysis was performed for the films taken from Plan 1b. We would expect 
to see an improvement in DTA’s due to the film channels being offset from the beam paths, and 
there being a 15 degree couch kick removing the axial film from being directly in line with either 
field. Analysis of the axial films for Plan 1b trial 2 first reveals that there is a 2.3mm average 
distance over the specified dose levels on the posterior side of the profile in Figure 3-35, which is 
drawn through the intersection of the beams, therefore the posterior edge of the profile is composed 
of regions taken from the lateral sides of the beam from each field, and not entirely from the distal 
end of the beams. In Figure 3-36, the right left profile shows an average of 1.4mm difference with 
the largest values coming from around the 80% dose level region. The uptick on the tail of the 
Patient right side profile is due to the dose overshoot of the dose “horns” and the beam located at 80 
degrees. 
 
Figure 3.35 Plan 1b Trial 2 Anterior Posterior Profile Axial Plane 
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Figure 3.36 Plan 1b Trial 2 Right Left Profile Axial Plane 
The film for the coronal plane shows similar results to the one from the orthogonal beam 
plan, in regards to the superior inferior direction. This was also expected as this plane is not directly 
oriented with the beam path, and therefore no real degradation due to LET or Distal edge degradation 
should be seen. The DTA for the superior and inferior sides are 2.3mm and 0.2mm respectively, 
shown in Figure 3-37. The Right left profile, Figure 3-38, shows an average DTA over the dose 
region with 0.9mm on the patient right side, exhibiting the same crossover effect seen in the Urie, 
1986 paper. (Urie, et al. 1986) 
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Figure 3.37 Plan 1b Trial 2 Superior Inferior Profile Coronal Plane 
 
Figure 3.38 Plan 1b Trial 2 Right Left Profile Coronal Plane 
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The film for the sagittal plane is very similar to the coronal film. The Anterior posterior 
profile, Figure 3-39, showed a DTA of 2.4mm on the posterior side of the profile, where the superior 
and inferior sides of Figure 3-40 are 1.1mm and 0.8mm respectively.  The remaining DTA analysis 
for the other two trials of Plan 1b, as well as a summary of the DTA results, is located in the 
Appendix. 
 
 
Figure 3.39 Plan 1b Trial 2 Anterior Posterior Profile Sagittal Plane 
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Figure 3.40 Plan 1b Trial 2 Superior Inferior Profile Sagittal Plane 
Comparing the averages of the three trials for Plan 1b, and utilizing the pass fail criteria of 
3mm from the hypothesis, shown in Table 21, has no failures. 
Plan 1b DTA Averages 
Axial  Right Left Profile Anterior Posterior Profile 
  Patient Right  2.4 Posterior 2.3 
  Patient Left 1.7 Anterior 0.9 
Coronal Right Left Profile Superior Inferior Profile 
  Patient Right  0.4 Superior 1.8 
  Patient Left 0.5 Inferior 0.6 
Sagittal Anterior Posterior Profile Superior Inferior Profile 
  Posterior 1.9 Superior 1.7 
  Anterior  0.6 Inferior 1.0 
Table 21 Plan 1b DTA averaged over 3 trials 
The only individual failure is on the axial film of trial 1, which appears to be misaligned as 
evident by the right left profile, shown in Figure 3-41. This is entirely possible as the axial film is 
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pricked by hand and is only aligned by the phantom alignment notch, which might cause the film to 
rotate when compression is applied.  For all 6 trials of the two plans of the phantom, this only 
occurred this one time Subtracting the offset of 3.5mm from the patient left side from the 4.7mm of 
the patient right side, would give a passing value of 1.2mm. 
 
Figure 3.41 Plan 1b Trial 1 Right Left Profile Axial Plane 
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CHAPTER 4: CONCLUSIONS 
4.1 Summary 
This project was intended to design and test a proton equivalent lung insert that could be 
used inside the existing RPC Thorax phantom to allow for auditing of proton lung therapy treatment 
procedures.  The guidelines set forth in the hypothesis for this were to have no more than a 5%/3mm 
difference between the measured dose and the calculated dose with a reproducibility of 5%.  
Selecting a proton equivalent material and designing a new insert was the first part of this 
project.  Relative stopping powers, physical density, and HU’s of existing materials were evaluated, 
and extra heavy balsa wood, a material with comparable density and HU, was selected.  The relative 
stopping power of the balsa was measured to be 0.313 and compared favorably with the calibrated 
HU-RLSP curve that is used by the Eclipse treatment planning system at the PTC-H. A treatment 
plan was then developed and the Phantom was treated utilizing two different plans.  
The LET of film based on orientation was then tested by submersing film both parallel and 
perpendicularly in a water phantom.   Parallel film irradiation was explored utilizing two different 
methods of film alignment. A 24.3% difference between the original method and the alternate 
method was observed and probably was related to beam malfunctioning. When compared to the ion 
chamber readings, both parallel and perpendicular orientations displayed a quenching effect 
underperforming the ion chamber, with the alternate parallel orientation showing an average 31.0 % 
difference and the perpendicular showing an average of 14.7% difference. 
The phantom was simulated using a free breathing technique common to all lung patients at 
M. D. Anderson. The first plan consisted of treatment fields at orthogonal angles, 0 and 90 degrees, 
with a 0 degree couch kick. This was put in place to verify if there would be noticeable differences 
due to distal edge degradation with the film channels in the insert parallel to the treatment fields. The 
second plan consisted of two beams at 10 and 80 degrees, with a couch kick of -15 degrees, thereby 
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placing all of the film channels at orientations that ensure no parallel artifacts might be present.  Both 
plans were developed to mimic treatment pans on patients, and as such the compensators were 
smeared by 6mm and the apertures were expanded by 10mm. both of the plans were then scaled to 
deliver 200 cGy to the tumor target for 1 fraction. The phantom was then irradiated 3 times for each 
plan for a total doe to the tumor target of 600 cGy.. 
A separate plan was then created to see if contouring and setting the PVC shell to a value 
that corresponds with the HU-RLSP curve from Eclipse would show improvement.  Since the shell 
in that region is only 6.35 mm thick, the HU number was changed and due the increased treatment 
area caused by the smearing and expansion of the compensators and apertures, it did not result in any 
difference when the beam parameters were calculated. A comparison of the two plans showed that 
no pixels were different with a 5%/3mm gamma criteria. Gamma analysis was then performed 
utilizing the Contoured PVC dose plan, and no noticeable differences were found. 
For both plans the TLD values of the PTV region were within 7% of the dose calculated by 
Eclipse.   The gamma analysis for Plan 1a at the 5%3mm criteria, revealed individual plane passing 
percentages much lower than 80%, which was expected due to the alignment of the film and the 
beams. The average of the three plane averages was 71% for Plan 1a.  The gamma analysis for Plan 
1b showed better results for each individual plane, even though they also were less than the 80% 
suggested by the pass criteria. The averages for the individual planes ranged from 72% to 78% with 
the average of the three plane average having a passing rate of 76%. The plans were then compared 
utilizing the RPC conventional Lung treatment guidelines set forth by the RTOG, 5%/5mm, with 
80% pass rate per plane and an overall pass rate of 85%. Utilizing this criteria Plan 1b was passing 
for all 3 trials, with an average of the three plane average of 89%.  Plan 1a, however, failed the 
individual plane criteria even at the lower criteria.  
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Evaluating the DTA using 2D profiles gives a better picture of what is happening in the 
gamma analysis. Looking at the profiles drawn parallel to the treatment fields shows there is not just 
a dependence on the LET of the film due to quenching, but also because of distal edge degradation. 
The overall poor comparison of the film with the plan is primarily caused by the TPS’s inability to 
accurately account for the inhomogeneities of the phantom materials. 
4.2 Conclusions 
The hypothesis of this project was to modify the existing RPC thorax phantom for usage in 
proton beams. Based on the design of the new phantom insert and the properties of protons, it is 
recommended that when the treatment plans are created for evaluation, that the beams need to be 
placed in orientations that are not parallel to the film channels. This can be accomplished by placing 
the beams at 10 degrees and 80 degrees, or by placing them at orthogonal angles such as 30 and 120 
degrees, being careful not to allow the couch to enter the path of the beam.  
 The pass criteria set forth in the hypothesis was 5%/3mm with 5% reproducibility, however 
pass rates were not stipulated. The reproducibility of dose to the tumor site, as displayed by the TLD 
readings is under 7%. However, when applying the pass rates of an 80% for each single plane, and a 
85% overall pass rate to a patient equivalent plan where the smearing and expansion of the 
compensators and apertures, this pass criteria cannot be met. At this point we do not know if the 
failure is caused by the inadequacy of the TPS or a failure of the dosimetry system. The failure of the 
dosimetry system could be due  to a combination of the effects of LET on the film, distal edge 
degradations caused by inhomogenities of the phantom, and by dose “horns” introduced by the 
patient equivalent plan, that cause multiple pixel failures downstream of the tumor target. .However,  
when utilizing the existing criteria set forth by the RTOG for photons of 5%/5mm at 80% pass for 
each single plane, and a 85% overall pass rate is achievable on a patient equivalent plan, as long as 
the beams are placed correctly..  
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At this time, when utilizing a patient equivalent plan either the pass rates should be lowered 
or the phantom should be treated utilizing a tighter PTV that does not allow for smearing and 
expansion that is traditionally performed on patient exams. Either of these recommendations should 
allow for the effective evaluation of proton therapy treatment procedures for lung tumors. Further 
studies could verify that a treatment plan with a tighter PTV can pass at a 5%/3mm with standard 
pass rates. 
4.3 Future Work 
The thorax phantom with the modified imaging/dosimetry insert can be an extremely 
valuable tool for use in evaluating proton therapy procedures. Utilizing a motion sled, existing 
patient equivalent techniques could be utilized to verify motion gating. Also developing and treating 
a plan with a tighter PTV to verify passing conditions without the presence of dose overshoot could 
be evaluated. As for improvements to the insert, applying some type of secondary alignment notch 
could prevent possible slippage of the axial film, which likely caused the only failure in DTA 
profiles for Plan 1b. 
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CHAPTER 5: APPENDIX 
5.1 Gamma Analysis – 5%/3mm 
5.1.1 PLAN 1A 
 
Figure 5.1 Plan 1a Trial 1 Axial Gamma Analysis 
 
Figure 5.2 Plan 1a Trial 1 Coronal Gamma Analysis 
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Figure 5.3 Plan 1a Trial 1 Sagittal Gamma Analysis 
 
Figure 5.4 Plan 1a Trial 3 Axial Gamma Analysis 
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Figure 5.5 Plan 1a Trial 3 Coronal Gamma Analysis 
 
Figure 5.6 Plan 1a Trial 3 Sagittal Gamma Analysis 
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5.1.2 PLAN 1A – PVC CONTOURED 
 
Figure 5.7 Plan 1a Trial 1 Axial Gamma Analysis 
 
Figure 5.8 Plan 1a Trial 1 Coronal Gamma Analysis 
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Figure 5.9 Plan 1a Trial 1 Sagittal Gamma Analysis 
 
Figure 5.10 Plan 1a Trial 3 Axial Gamma Analysis 
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Figure 5.11 Plan 1a Trial 3 Coronal Gamma Analysis 
 
Figure 5.12 Plan 1a Trial 3 Sagittal Gamma Analysis 
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5.1.3 PLAN 1B 
 
Figure 5.13 Plan 1b Trial 1 Axial Gamma Analysis 
 
Figure 5.14 Plan 1b Trial 1 Axial Gamma Analysis 
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Figure 5.15 Plan 1b Trial 1 Sagittal Gamma Analysis 
 
Figure 5.16 Plan 1b Trial 3 Axial Gamma Analysis 
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Figure 5.17 Plan 1b Trial 3 Coronal Gamma Analysis 
 
Figure 5.18 Plan 1b Trial 3 Sagittal Gamma Analysis 
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5.1.4 PLAN 1B- PVC CONTOURED 
 
Figure 5.19 Plan 1b Trial 1 Axial Gamma Analysis 
 
Figure 5.20 Plan 1b Trial 1 Axial Gamma Analysis 
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Figure 5.21 Plan 1b Trial 1 Sagittal Gamma Analysis 
 
Figure 5.22 Plan 1b Trial 3 Axial Gamma Analysis 
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Figure 5.23 Plan 1b Trial 3 Coronal Gamma Analysis 
 
Figure 5.24 Plan 1b Trial 3 Sagittal Gamma Analysis 
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5.2 DTA Profile Comparisons 
5.2.1 PLAN 1A 
Trial 1 
Axial  Right Left Profile Anterior Posterior Profile 
  Patient Right  5.8 Posterior 6.3 
  Patient Left 1.2 Anterior 0.2 
Coronal Right Left Profile Superior Inferior Profile 
  Patient Right  2.2 Superior 1.2 
  Patient Left 1.3 Inferior 1.7 
Sagittal Anterior Posterior Profile Superior Inferior Profile 
  Posterior 1.8 Superior 0.9 
  Anterior  1.3 Inferior 1.9 
Trial 2 
Axial  Right Left Profile Anterior Posterior Profile 
  Patient Right  5.8 Posterior 4.9 
  Patient Left 1.6 Anterior 0.1 
Coronal Right Left Profile Superior Inferior Profile 
  Patient Right  2 Superior 1.6 
  Patient Left 0.5 Inferior 1.1 
Sagittal Anterior Posterior Profile Superior Inferior Profile 
  Posterior 2.5 Superior 1.2 
  Anterior  0.4 Inferior 1 
Trial 3 
Axial  Right Left Profile Anterior Posterior Profile 
  Patient Right  4.4 Posterior 5.5 
  Patient Left 0.8 Anterior 0.4 
Coronal Right Left Profile Superior Inferior Profile 
  Patient Right  0.4 Superior 1.1 
  Patient Left 0.1 Inferior 0.6 
Sagittal Anterior Posterior Profile Superior Inferior Profile 
  Posterior 1.6 Superior 1 
  Anterior  1.1 Inferior 1.3 
Table 22 DTA values per film per profiles for Plan 1a, in mm. 
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Figure 5.25 Plan 1a Trial 1 Anterior Posterior Profile Axial Plane 
 
Figure 5.26 Plan 1a Trial 1 Right Left Profile Axial Plane 
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Figure 5.27  Plan 1A Trial 1 Right Left Profile Coronal Plane 
 
 
Figure 5.28 Plan 1A Trial 1 Superior Inferior Coronal Plane 
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Figure 5.29 Plan 1A Trial 1 Anterior Posterior Sagittal Plane 
 
 
Figure 5.30 Plan 1A Trial 1 Superior Inferior Sagittal Plane 
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Figure 5.31 Plan 1A Trial 1 Right Left Profile Axial Plane 
 
 
Figure 5.32 Plan 1A Trial 3 Anterior Posterior Axial Plane 
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Figure 5.33 Plan 1A Trial 3 Right Left Coronal Plane 
 
 
Figure 5.34 Plan 1A Trial 3 Superior Inferior Coronal Plane 
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Figure 5.35 Plan 1A Trial 3 Anterior Posterior Sagittal Plane 
 
 
Figure 5.36 Plan 1A Trial 3 Superior Inferior Sagittal Plane  
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5.2.2 PLAN 1B  
Trial 1 
Axial  Right Left Profile 
Anterior Posterior 
Profile 
  Patient Right  4.7 Posterior 2.8 
  Patient Left 3.5 Anterior 1.1 
Coronal Right Left Profile 
Superior Inferior 
Profile 
  Patient Right  0.6 Superior 1.3 
  Patient Left 0.3 Inferior 0.8 
Sagittal Anterior Posterior Profile 
Superior Inferior 
Profile 
  Posterior 1.2 Superior 2.1 
  Anterior  1 Inferior 0.8 
Trial 2 
Axial  Right Left Profile 
Anterior Posterior 
Profile 
  Patient Right  1.4 Posterior 2.3 
  Patient Left 0.6 Anterior 0.5 
Coronal Right Left Profile 
Superior Inferior 
Profile 
  Patient Right  0.2 Superior 2.3 
  Patient Left 0.9 Inferior 0.2 
Sagittal Anterior Posterior Profile 
Superior Inferior 
Profile 
  Posterior 2.4 Superior 1.1 
  Anterior  0 Inferior 0.8 
Trial 3 
Axial  Right Left Profile 
Anterior Posterior 
Profile 
  Patient Right  1.1 Posterior 1.9 
  Patient Left 1.1 Anterior 1 
Coronal Right Left Profile 
Superior Inferior 
Profile 
  Patient Right  0.5 Superior 1.7 
  Patient Left 0.2 Inferior 0.7 
Sagittal Anterior Posterior Profile 
Superior Inferior 
Profile 
  Posterior 2 Superior 2 
  Anterior  0.7 Inferior 1.5 
Table 23  DTA values per film per profiles for Plan 1b, in mm. 
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Figure 5.37 Plan 1b Trial 1 Right Left Axial Plane 
 
 
Figure 5.38 Plan 1b Trial 1 Anterior Posterior Axial Plane 
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Figure 5.39 Plan 1b Trial 1 Right Left Coronal Plane 
 
 
Figure 5.40 Plan 1b Trial 1 Superior Inferior Coronal Plane 
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Figure 5.41 Plan 1b Anterior Posterior Sagittal Plane 
 
 
Figure 5.42 Plan 1b Trial 1 Superior Inferior Sagittal Plane 
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Figure 5.43 Plan 1b Trial 3 Right Left Axial Plane 
 
 
Figure 5.44 Plan 1b Trial 3 Anterior Posterior Axial Plane 
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Figure 5.45 Plan 1b Trial 3 Right Left Coronal Plane 
 
 
Figure 5.46 Plan 1b Trial 3 Superior Inferior Coronal Plane 
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Figure 5.47 Plan 1b Trial 3 Anterior Posterior Sagittal Plane 
 
 
Figure 5.48 Plan 1b Trial 3 Superior Inferior Sagittal Plane 
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5.49 Monitor Unit Calculation Sheet 
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